MODIFIED PLANTS

Abstract

The present invention relates to conferring enhanced pathogen resistance in wheat plants using targeted genome modification.

Claims

1. A wheat plant, plant part or plant cell that has increased resistance to powdery mildew compared to a wild type wheat plant and comparable yield under non-disease conditions compared to a wild type wheat plant wherein said plant comprises a loss of function mutation in the coding regions of two alleles selected from TaMLO-A1, TaMLO-B1 and TaMLO-D1 and reduced expression of the third TaMLO allele.

2. A wheat plant, plant part or plant cell according to claim 1 wherein said third TaMLO allele does not contain a mutation in the coding region compared to the wild type allele.

3. A wheat plant, plant part or plant cell according to claim 1 wherein said plant comprises a loss of function mutation in the coding regions of TaMLO-A1 and TaMLO-D1 and reduced expression of TaMLO-B1.

4. A wheat plant, plant part or plant cell according to claim 3 wherein said reduced expression of TaMLO-B1 is caused by a mutation in the regulatory region of TaMLO-B1, a mutation in a gene downstream in the MLO pathogen response pathway or an epigenetic factor.

5. A wheat plant, plant part or plant cell according to claim 1 wherein said mutation is introduced using targeted genome modification wherein preferably said mutation is introduced using a rare-cutting endonuclease, for example a TALEN, ZFN or CRISPR/Cas9.

6. (canceled)

7. A wheat plant, plant part or plant cell according to claim 5 wherein said mutation is introduced using a TALEN and wherein said TAL effector binds to TCGCTGCTGCTCGCCGTgacgcaggaccccatctcCGGGATATGCATCTCCGA (SEQ ID NO. 13).

8. A wheat plant, plant part or plant cell according to claim 1 wherein said mutation is an insertion, deletion or substitution.

9. A wheat plant, plant part or plant cell according to claim 1 wherein said wheat plant is selected from the list that includes, but is not limited to, Triticum aestivum, T. aethiopicum, T. araraticum, T. boeoticum, T. carthlicum, T. compactum, T. dicoccoides, T. dicoccum, T. durum, T. ispahanicum, T. karamyschevii, T. macha, T. militinae, T. monococcum, T. polonicum, T. repens, T. spelta, T. sphaerococcum, T. timopheevii, T. turanicum, T. turgidum, T. urartu, T. vavilovii and T. zhukovskyi.

10. A wheat plant, plant part or plant cell according to claim 1 wherein said mutation is in a TaMLO-A1 allele having a wild type sequence of SEQ ID NO. 1 or a functional variant thereof or in a TaMLO-B allele having a wild type sequence of SEQ ID NO. 2 or a functional variant thereof or in a TaMLO-D allele having a wild type sequence of SEQ ID NO. 3 or a functional variant thereof, wherein the functional variant has at least 75% sequence identity to said wild type sequence.

11. (canceled)

12. (canceled)

13. A wheat plant, plant part or plant cell according to claim 1 wherein said plant does not comprise a transgene.

14. A wheat plant, plant part or plant cell according to claim 1 comprising a Tamlo-a sequence as shown in SEQ ID No. 38, a Tamlo-d sequence as shown in SEQ ID No. 39 and a TaMLO-B1 sequence having a wild type sequence of SEQ ID NO. 2.

15. A wheat plant, plant part or plant cell or part thereof wherein said wheat genotype has been deposited under CGMCC Accession Number 10951.

16. A plant part or plant seed according to a claim 1.

17. A method for producing a wheat plant, plant part or plant cell with increased resistance to powdery mildew compared to a wild type plant and comparable yield under non-disease conditions compared to a wild type wheat plant using targeted genome modification comprising introducing a loss of function mutation into the coding regions of two MLO alleles selected from TaMLO-A1, TaMLO-B1 and TaMLO-D1 and decreasing expression of the third TaMLO allele.

18. A method according to claim 17 wherein said third TaMLO allele does not comprise a mutation in the coding region compared to the wild type allele.

19. A method according to claim 17 comprising introducing a loss of function mutation in the coding regions of TaMLO-A1, TaMLO-D and reducing expression of TaMLO-B1.

20. A method according to claim 19 wherein TaMLO-B1 comprises a mutation in the regulatory region.

21. A method according to claim 17 wherein said mutation is introduced using a rare-cutting endonuclease, for example a TALEN, ZFN or CRISPR/Cas9.

22. A method according to claim 21 wherein screening for induced targeted mutations in a TaMLO-A1, TaMLO-B1 and/or TaMLO-D1 allele comprises obtaining a nucleic acid sample from a said plant and carrying out nucleic acid amplification and optionally restriction enzyme digestion to detect a mutation in a TaMLO-A1, TaMLO-B1 and/or TaMLO-D1 allele.

23. A method according to claim 22 comprising confirming the presence of the mutation by sequencing the TaMLO-A1, TaMLO-B1 and/or TaMLO-D1 nucleic acid.

24. A method according to claim 21 comprising the further step of regenerating a plant and screening for a plant resistant to powdery mildew.

25. A method for conferring resistance to powdery mildew to a wheat plant comprising producing a plant according to claim 17.

26. The method according to claim 17 wherein said plant does not contain a transgene.

27. A plant, plant part or plant cell obtained or obtainable by a method of claim 17, wherein preferably said plant part is a seed.

28. (canceled)

29. An isolated Tamlo nucleic acid sequence as defined in SEQ ID NO. 38 or 39.

Description

DESCRIPTION OF FIGURES

[0019] The invention is further illustrated in the following non-limiting figures.

[0020] FIG. 1. TaMLO homologous triple mutants When TaMLO homologous triple mutants.sup.42 (tamlo-aabbdd) were grown under axenic (disease free) conditions, these triple mutant plants show development related phenotypes, including cell death and senescence-like chlorosis about at 12 weeks.

[0021] FIG. 2. Targeted knock-out of TaMLO genes using TALENs. (a) Sites within a conserved region of exon 2 of wheat TaMLO homoeologs targeted by TALENs. The TALEN-targeted sequences in MLO-A1, MLO-B1 and MLO-D1 are underlined, and the Avail restriction site in the spacer is GGACC (SEQ ID NO. 43, SEQ ID NO. 44, SEQ ID NO. 45). There are three SNPs, two are in the spacer region. The first is C/G/G respectively directly adjacent to the underlined 5 region. The second is A/C/A 3 of the Avail region following residue C directly adjacent to the Avail region. The third one lies near the far right of the TALEN binding site (penultimate 3 residue). (b) Mutations in TaMLO homologous triple mutants are located in the A and D coding sequences. Tamlo-R (with genetic profile tamlo-AaBBDd) is heterozygous in genome A and D. No mutation was identified at the target site in genome B in T0 plants (SEQ ID NO. 46, SEQ ID NO. 47, SEQ ID NO. 48). (c) Phenotype of homozygous T1 mutant lines. When all the 7 homozygous T1 plants were challenged with conidiospores of a virulent Bgt race, only the homozygous plant R32 confers resistance to powdery mildew. R32 did not display the senescence-like chlorosis, and the plant grew as vigorously as the wild type.

[0022] FIG. 3. Phenotype of homozygous T1 mutant lines. All the progeny of R32 showed resistance to Bgt, and about of R26, R40 and R54 offsprings were resistant to the Bgt. All the progeny of R51 were susceptible to the Bgt. In contrast to fully resistant mutant tamlo-aabbdd plants, the resistant mutant plants allow the low-level growth of sporulating Bgh.

[0023] FIG. 4. Transcription level of mlo in mutant lines. Transcription of the TaMLO protein of genome B (TaMLO-B1) of these resistant plants is lower compared with wild type.

[0024] FIG. 5. DNA sequence of the GFP donor cassette. The cassette contains the GFP coding sequence (in bold) and the CaMV 35S terminator sequence (in italics), and is flanked by two T-MLO target sequences (underlined) at both ends.

[0025] FIG. 6. Vector sequences. (a) The sequence of UBI-attr1-attr2-Nos in vector pYP010: 4047 bp. The sequence of Ubi-1 is underlined is and the attr1 and attr2 are in italics. Nos is indicated in bold. (SEQ ID NO. 7) (b) The sequence of TAL-L in vector pZHY500: 2202 bp. The sequences of N terminal and C terminal are underlined. TAL-L is labelled in bold. (SEQ ID NO. 8) (c) The sequence of TAL-R in vector pZHY501: 2304 bp. The sequences of N terminal and C terminal are indicated. TAL-R is labelled in bold. (SEQ ID NO. 9) (d) The sequence of TALENs (TAL-L+TAL-R) in vector pZHY013. Sequences in italics are attr1 and attr2. The sequences of N terminal and C terminal parts are indicated underlined. TAL-L and TAL-R are in bold. The Fokl sequences are in italics and underlined. T2A motif is underlined and in bold. (SEQ ID NO.10).

[0026] FIG. 7. Genetic mapping.

[0027] FIG. 8: Phenotypic analysis of mlo mutant R32. (A) Thousand kernel weights (TKW) of R32 mutant in Bobwhite background compared to wildtype Bobwhite control (WT). Values are means.d**P<0.01 (t-tests). (B) (C) and (D), the seed circumference, length and width of R32 mutant plants compared to WT. All the data are from 9 line replicates for R32 and WT.

[0028] FIG. 9: Phenotypic analysis of mlo-aabbdd mutant. (A) Thousand kernel weights (TKW) of mlo-aabbdd mutant in Kn199 background compared to wild type Kn199(WT). (B) (C) and (D), the seed circumference, length and width of mlo-aabbdd mutant plants compared to WT. All the data are from 8 lines replicates for mlo-aabbdd and WT.

DETAILED DESCRIPTION

[0029] The present invention will now be further described. In the following passages, different aspects of the invention are defined in more detail. Each aspect so defined may be combined with any other aspect or aspects unless clearly indicated to the contrary. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being preferred or advantageous.

[0030] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of botany, microbiology, tissue culture, molecular biology, chemistry, biochemistry and recombinant DNA technology, bioinformatics which are within the skill of the art. Such techniques are explained fully in the literature.

[0031] As used herein, the words nucleic acid, nucleic acid sequence, nucleotide, nucleic acid molecule or polynucleotide are intended to include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), natural occurring, mutated, synthetic DNA or RNA molecules, and analogs of the DNA or RNA generated using nucleotide analogs. It can be single-stranded or double-stranded. Such nucleic acids or polynucleotides include, but are not limited to, coding sequences of structural genes, anti-sense sequences, and non-coding regulatory sequences that do not encode mRNAs or protein products. These terms also encompass a gene. The term gene, allele or gene sequence is used broadly to refer to a DNA nucleic acid associated with a biological function. Thus, genes may include introns and exons as in the genomic sequence, or may comprise only a coding sequence as in cDNAs, and/or may include cDNAs in combination with regulatory sequences. Thus, according to the various aspects of the invention, genomic DNA, cDNA or coding DNA may be used. In one embodiment, the nucleic acid is cDNA or coding DNA.

[0032] The terms peptide, polypeptide and protein are used interchangeably herein and refer to amino acids in a polymeric form of any length, linked together by peptide bonds.

[0033] The term allele designates any of one or more alternative forms of a gene at a particular locus. Heterozygous alleles are two different alleles at the same locus. Homozygous alleles are two identical alleles at a particular locus. A wild type allele is a naturally occurring allele.

[0034] For the purposes of the invention, a mutant plant is a plant that has been altered compared to the naturally occurring wild type (WT) plant. Specifically, the endogenous nucleic acid sequences of each of the MLO homologs in wheat (wild type nucleic acid sequences TaMLO-A1, TaMLO-B1 and TaMLO-D1) have been altered compared to wild type sequences using mutagenesis methods as described herein. This causes inactivation of the endogenous Mlo genes and thus disables Mlo function. Such plants have an altered phenotype and show resistance or increased resistance to Pm compared to wild type plants. Therefore, the resistance is conferred by the presence of mutated endogenous TaMLO-A1, TaMLO-B1 and TaMLO-D1 genes in the wheat plant genome which has been specifically targeted using targeted genome modification and is not conferred by the presence of transgenes expressed in wheat.

[0035] As used herein, wild type nucleic acid sequences of wild type alleles are designated using capital letters, that is TaMLO-A1, TaMLO-B1 and TaMLO-D1. Mutant mlo nucleic acid sequences use non-capitalisation, that is taml-aa1, tamlo-bb1, tamlo-dd1. Wheat plants of the invention are mutant plants compared to wild type plants which comprise and express mutant mlo alleles.

[0036] mlo mutations that down-regulate or disrupt functional expression of the wild-type Mlo sequence are recessive, such that they are complemented by expression of a wild-type sequence. Thus Mlo function can be determined by assessing the level of constitutive defence response and/or susceptibility of the plant to a pathogen such as, for example, powdery mildew. Thus, according to the invention, a putative nucleotide sequence with Mlo function can be tested upon complementation of a suitable mlo mutant. The term mlo function is used to refer to sequences which confer a mlo mutant phenotype on a plant. The capitalisation of Mlo and non-capitalisation of mlo is thus used to differentiate between wild-type and mutant function.

[0037] A mlo mutant phenotype according to the invention is characterised by the exhibition of an increased resistance against Pm. In other words, a mlo mutant according to the invention confers resistance to the pathogen causing Pm. Moreover, the mutant according to the invention is characterised in that it does not show any negative phenotype compared to the wild type which impacts on crop yield and quality, when grown under disease free conditions. In other words, the mutants of the invention do not show any yield and quality penalties compared to a wild type (wt) plant when grown under disease free conditions.

[0038] A negative phenotype compared to the wild type which impacts on crop yield and quality includes senescence-like phenotypes, reduced growth or reduced seed yield compared to a wild type plant. Senescence-like phenotypes can be assessed through the appearance of chlorosis. The reduction can be 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% or more.

[0039] A wild type wheat plant is a plant that does not have any mutant M/o alleles.

[0040] The aspects of the invention involve targeted mutagenesis methods, specifically genome editing, and exclude embodiments that are solely based on generating plants by traditional breeding methods. As explained herein, the disease resistant trait is not due to the presence of a transgene.

[0041] The inventors have generated mutant wheat lines with mutations inactivating all three MLO homoeoalleles which confer heritable resistance to powdery mildew fungus so that no functional TaMLO-B1, TaMLO-A1 or TaMLO-D1 protein is made. These plants do not show senescence like phenotypes which negatively impact on crop yield and quality. Thus, the invention relates to these mutant wheat lines and related methods.

[0042] As shown in FIG. 1, when TaMLO homologous triple mutants.sup.42 (genotype: tamlo-aabbdd) were grown under axenic (disease free) conditions, these triple mutant plants show development related phenotypes, including cell death and senescence-like chlorosis at about 12 weeks. These phenotypes also occurred, as previously reported, in barley.sup.42 and Arabidopsis.sup.44. The senescence-like phenotypes may negatively influence wheat crop yield and quality.

[0043] However, in wheat mlo mutants generated using TALENs, we identified one line, Tamlo-R (with genetic profile tamlo-AaBBDd), which is heterozygous in genome A and D, but which does not have a mutation at the target site in genome B in T0 plants (FIG. 2). After segregation, in the T1 generation, we identified 7 plants homozygous for the mutation in genome A and D (tamlo-aaBBdd), named as R4, R25, R26, R32, R40, R51 and R54. When all the 7 homozygous T1 plants were challenged with conidiospores of a virulent Bgt race, we found that only the homozygous plant R32 confers resistance to powdery mildew (FIG. 2). Interestingly, R32 did not display the senescence-like chlorosis, and the plant grew as vigorously as the wild type in disease free conditions.

[0044] We also assessed the resistance to powdery mildew of offspring of all the homozygous mutant progeny of line Tamlo-R (R4, R25, R26, R32, R40, R51 and R54). We found that all the progeny of R32 showed resistance to Bgt, and about of R26, R40 and R54 offspring were resistant to the Bgt. All the progeny of R51 were susceptible to the Bgt (FIG. 3). In contrast to fully resistant mutant tamlo-aabbdd plants, the resistant mutant plants allow the low-level growth of sporulating Bgh (FIG. 3.). This phenotype was similar to the well-known and widely used (in agriculture) barley mlo mutant mlo-11.sup.42. None of these powdery mildew resistant mutant plants showed developmentally related negative phenotypes, such as cell death or senescence-like chlorosis.

[0045] We assessed the level of transcription of mlo for these mutants in genome A, B and D, respectively. We found that the transcription of the TaMLO protein of genome B (TaMLO-B1) of these resistant plants was lower compared with wild type (FIG. 4). This result is also similar to that described in barley mutant mlo-11.sup.42. Accumulation of both Mlo-B transcript and protein is impaired in the R32 line, but the mutation does not reside in the coding region of TaMLO-B1.

[0046] Thus, the invention relates to a wheat plant, plant part or plant cell generated by genome editing techniques which has increased resistance to powdery mildew compared to a wild type what plant and which does not show growth or yield penalties under non-disease conditions compared to a wild type plant. Compared to fully resistant mutant tamlo-aabbdd plants, such plant shows better growth and/or yield under non-disease conditions. Thus, yield of the plants of the invention is comparable to the yield of wild type plants under non-disease conditions, that is where the plant is not exposed to powdery mildew. This means that there is essentially no reduction in yield or no more than 1-5% reduction in yield.

[0047] Specifically, in a first aspect, the invention relates to a wheat plant, plant part or plant cell that has increased resistance to powdery mildew compared to a wild type plant and comparable yield under non-disease conditions compared to a wild type wheat plant wherein said plant comprises a loss of function mutation in the coding regions of two alleles selected from TaMLO-A1, TaMLO-B1 and TaMLO-D1 and reduced expression of the third TaMLO allele or inactivated function of the third TaMLO protein.

[0048] In one embodiment, the coding region of said third TaMLO allele does not contain a mutation as compared to the coding region of the TaMLO allele from a wild type plant.

[0049] In one embodiment, the coding region of said third TaMLO allele does not contain a mutation as compared to the coding region of TaMLO allele from a wild type plant that renders the protein non-functional or reduces gene expression.

[0050] For example, the third TaMLO allele may comprise a mutation that reduces expression of the third TaMLO allele or inactivates function of the third third TaMLO protein wherein said mutation is not in the coding region of said third TaMLO allele.

[0051] In another aspect, the invention relates to a wheat plant, plant part of plant cell that has increased resistance to powdery mildew compared to a wild type plant comprising a loss of function mutation in the coding regions of two alleles selected from TaMLO-A1, TaMLO-B1 and TaMLO-D1 and reduced expression of the third TaMLO allele wherein said third TaMLO allele does not have a mutation in its coding region.

[0052] In one embodiment, the invention relates to a wheat plant, plant part or plant cell wherein said plant comprises a loss of function mutation in the coding regions of TaMLO-A1 and TaMLO-D1 and reduced expression of TaMLO-B1 wherein the coding region of TaMLO-B1 does not contain a mutation as compared to the coding region of TaMLO-B1 from a wild type plant.

[0053] The loss of function mutations in the two MLO alleles result in impaired transcript and/or protein accumulation. Expression of the third TaMLO allele is reduced compared to wild type expression, for example by at least 5-50%. In one embodiment, there is essentially no expression. A mutation that reduces expression of or otherwise inactivates the third TaMLO allele does not reside in the coding region of said allele, but results in impaired accumulation of the transcript of the third TaMLO allele and/or impaired accumulation of the protein encoded by the third TaMLO allele. For example, the mutation may be in the regulatory region of the allele (for example in SEQ ID No. 40, 41 or 42 or 5 thereof). Alternatively, the mutation that inactivates the third TaMLO allele can be a mutation found in another gene in the pathway which interacts with said TaMLO allele, or due to epigenetic factors affecting the sequence of regulatory region. Thus, said reduced expression of the TaMLO allele, for example TaMLO-B1, is caused by a mutation in the regulatory region of the TaMLO allele, for example TaMLO-B1, a mutation in a gene downstream in the MLO pathogen response pathway or is due to an epigenetic factor.

[0054] Thus, the mutant wheat plant according to the invention is a triple mutant and comprises a genotype selected from tamlo-aaBBdd, tamlo-aabbDD or tamlo-AAbbdd. The triple mutants do not have a mutation in the coding region in one of the TaMLO alleles selected from TaMLO-A1, TaMLO-B1 and TaMLO-D1. Thus, the mutation cannot be found in an exon of said TaMLO allele.

[0055] The mutations are introduced into the wild type TaMLO alleles using targeted genome modification, preferably they are introduced simultaneously.

[0056] In one embodiment, said targeted genome modification comprises the use of SSNs. These may be selected from ZFNs, a rare-cutting endonuclease, for example a TALEN or CRISPR/Cas9.

[0057] Rare-cutting endonucleases are naturally or engineered proteins having endonuclease activity. These bind to nucleic acid target sequences which have a recognition sequence typically 12-40 bp in length. In one embodiment, the SSN is selected from a TALEN. In another embodiment, the SSN is selected from CRISPR/Cas9. This is described in more detail below.

[0058] The loss of function mutation may be a deletion or insertion (indels) with reference the wild type TaMLO-A1, TaMLO-B1 and TaMLO-D1 allele sequence are shown herein. The deletion may comprise 1-20, for example 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1, 12, 13, 14, 15, 16, 17, 18 or 20 nucleotides in one or more strand. The insertion may comprise 1-20, for example 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1, 12, 13, 14, 15, 16, 17, 18 or 20 nucleotides in one or more strand.

[0059] The plant of the invention includes plants wherein said plant is heterozygous for the each of the mutations. In a preferred embodiment however, said plant is homozygous for the mutations. Progeny that is also homozyous can be generated from these plants according to methods known in the art.

[0060] According to the various aspects of the invention, the wild type TaMLO-A1 allele comprises or consists of SEQ ID NO. 1 or a fragment or a functional variant thereof. The corresponding amino acid sequence is SEQ ID NO. 4. According to the various aspects of the invention, the wild type TaMLO-B1 allele comprises or consists of SEQ ID NO. 2 or a fragment or a functional variant thereof. The corresponding amino acid sequence is SEQ ID NO. 5. According to the various aspects of the invention, the wild type TaMLO-D1 allele comprises or consists of SEQ ID NO. 3 or a fragment or a functional variant thereof. The corresponding amino acid sequence is SEQ ID NO. 6.

[0061] The term functional variant of a nucleic acid or protein sequence as used herein, for example with reference to SEQ ID NOs: 1, 2 or 3 refers to a variant gene sequence or part of the gene sequence which retains the biological function of the full non-variant TaMLO allele and hence act to modulate responses to Pm. A functional variant also comprises a variant of the gene of interest encoding a polypeptide which has sequence alterations that do not affect function of the resulting protein, for example in non-conserved residues. Also encompassed is a variant that is substantially identical, i.e. has only some sequence variations, for example in non-conserved residues, to the wild type nucleic acid sequences of the alleles as shown herein and is biologically active.

[0062] As used herein, variants of a particular TaMLO nucleotide or amino acid sequence according to the various aspects of the invention will have at least about 50%-99%, for example at least 75%, for example at least 85%, 86%, 87%, 88%, 89%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% or more sequence identity to that particular non-variant TaMLO nucleotide sequence of the TaMLO allele as shown in SEQ ID NO. 1, 2 or 3 or 4, 5 or 6. Sequence alignment programs to determine sequence identity are well known in the art.

[0063] Also, the various aspects of the invention the aspects of the invention encompass not only a TaMLO nucleic acid sequence, but also fragment thereofs. By fragment is intended a portion of the nucleotide sequence or a portion of the amino acid sequence and hence of the protein encoded thereby. Fragments of a nucleotide sequence may encode protein fragments that retain the biological activity of the native protein and hence act to modulate responses to Pm.

[0064] In one embodiment, said mutation is introduced using a TALEN and wherein said TAL effector binds to a sequence in exon 2. In one embodiment, said TAL effector binds to TCGCTGCTGCTCGCCGTgacgcaggaccccatctcCGGGATATGCATCTCCGA (SEQ ID NO. 13).

[0065] Specifically, the binding site sequences of the second exon conserved region TaMLO-A, TaMLO-B and TaMLO-D to which these TALENs bind are:

TABLE-US-00001 (SEQIDNO.14) MLO-A:TCGCTGCTGCTCGCCGTcacgcaggacccaatctcCGGGATATG CATCTCCCA (SEQIDNO.15) MLO-B:TCGCTGCTGCTCGCCGTgacgcaggaccccatctcCGGGATATG CATCTCCGA (SEQIDNO.16) MLO-D:TCGCTGCTGCTCGCCGTgacgcaggacccaatctcCGGGATATG CATCTCCGA

[0066] The three SNPs are in bold and underlined. The Avail restriction site is shown in small letters and underlined.

[0067] A TALEN pair has for example the nucleic acid sequence SEQ ID NO. 11. The corresponding amino acid sequence is SEQ ID NO. 12.

[0068] In one embodiment, the plant of the invention comprises the mutations in TaMLO-A1 and/or TaMLO-D1 as shown in FIG. 1. In one embodiment, the mutations are as shown for tamlo-aaBBdd. In other words, in said wheat plant, the endogenous TaMLO-A1 allele is a mutant Tamlo-a1 allele and comprises SEQ ID NO. 38 the endogenous TaMLO-B1 allele is a wild type TaMLO-B1 allele and comprises SEQ ID NO. 2, and the endogenous TaMLO-D1 allele is a mutant Tamlo-d1 allele and comprises SEQ ID NO. 39.

[0069] In one aspect, the mutant plant is TALEN free.

[0070] The wheat plant is selected from the list that includes, but is not limited to, Triticum aestivum, T. aethiopicum, T. araraticum, T. boeoticum, T. carthlicum, T. compactum, T. dicoccoides, T. dicoccum, T. durum, T. ispahanicum, T. karamyschevii, T. macha, T. militinae, T. monococcum, T. polonicum, T. repens, T. spelta, T. sphaerococcum, T. timopheevii, T. turanicum, T. turgidum, T. urartu, T. vavilovii and T. zhukovskyi.

[0071] According to another embodiment the various aspects of the invention described herein, the plant is of the species Triticum aestivum or Triticum turgidum. According to another preferred embodiment, the plant belongs to the cultivar Bobwhite or the cultivar Don Pedro. More preferably, the cultivars BW208 and BW2003 (Bobwhite), which belong to the wheat species Triticum aestivum L. ssp aestivum, and the variety Don Pedro, which belongs to the wheat species Triticum turgidum L. ssp durum, are selected.

[0072] Bobwhite is the name of the cultivar obtained from the International Maize and Wheat Improvement Center (CIMMYT). BW208 and BW2003 are different Bobwhite lines. Don Pedro is a hard wheat variety, also from CIMMYT.

[0073] In particular, the invention relates to a mutant wheat genotype (Triticum aestivum), designated Accession Number CGMCC 10951 deposited under the Budapest Treaty at the China General Microbiological Culture Collection Center, Institute of Microbiology, Chinese Academy of Sciences, No. 1 Beichen West Road, Chaoyang District, Beijing 100101 on 29 Jun. 2015 by The Institute of Genetics and Developmental Biology Chinese Academy of Sciences, No. 1 Beichen West Road, Chaoyang District, Beijing 100101. The depositor's reference is Tamlo-R32. The deposited material was found viable in a test performed on 6 Jul. 2015. The invention thus relates to any what plants, parts thereof, including seeds, having this genotype. This mutant is described herein as Tamlo-aaBBdd (FIG. 1).

[0074] A triple mutant wheat plant according to the invention shows resistance or increased resistance to Pm compared to a control plant, preferably a wild type plant, because the mutations in impair accumulation of the TaMLO allele transcript and/or protein. The wheat plant according to the invention shows increased yield compared to a wild type control plant under biotic stress conditions wherein said stress is Pm.

[0075] Resistance can for example be assessed by assessing survival, growth, yield or size of pathogen colonies.

[0076] The terms increase, improve or enhance are interchangeable. Yield for example is increased by at least a 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10%, preferably at least 15% or 20%, more preferably 25%, 30%, 35%, 40% or 50% or more in comparison to a control plant. The term yield in general means a measurable produce of economic value, typically related to a specified crop, to an area, and to a period of time. Individual plant parts directly contribute to yield based on their number, size and/or weight, or the actual yield is the yield per square meter for a crop and year, which is determined by dividing total production (includes both harvested and appraised production) by planted square meters. The term yield of a plant may relate to vegetative biomass (root and/or shoot biomass), to reproductive organs, and/or to propagules (such as seeds) of that plant. Thus, according to the invention, yield comprises one or more of and can be measured by assessing one or more of: increased seed yield per plant, increased seed filling rate, increased number of filled seeds, increased harvest index, increased number of seed capsules and/or pods, increased seed size, increased growth or increased branching, for example inflorescences with more branches. Preferably, yield comprises an increased number of seed capsules/pods and/or increased branching. Yield is increased relative to control plants.

[0077] A control plant as used herein is a plant, which has not been modified according to the methods of the invention. Accordingly, the control plant does not have a mutant tamlo nucleic acid sequence as described herein. In one embodiment, the control plant is a wild type wheat plant. In another embodiment, the control plant is a plant that does not have a mutant tamlo nucleic acid sequence as described here, but is otherwise modified. The control plant is typically of the same plant species, preferably the same ecotype or the same or similar genetic background as the plant to be assessed.

[0078] The term plant as used herein encompasses whole plants, ancestors and progeny of the plants and plant parts, including seeds, fruit, shoots, stems, leaves, roots (including tubers), flowers, and tissues and organs, wherein each of the aforementioned comprise the gene/nucleic acid of interest. The term plant also encompasses plant cells, suspension cultures, protoplasts, callus tissue, embryos, meristematic regions, gametophytes, sporophytes, pollen and microspores, again wherein each of the aforementioned comprises the gene/nucleic acid of interest.

[0079] The invention also extends to harvestable parts of a mutant plant of the invention as described above such as, but not limited to seeds, leaves, flowers, stems and roots. The invention furthermore relates to products derived, preferably directly derived, from a harvestable part of such a plant, such as dry pellets or powders, oil, fat and fatty acids, flour, starch or proteins. The invention also relates to food products and food supplements comprising the plant of the invention or parts thereof.

[0080] In one aspect, the invention relates to a seed of a mutant wheat plant of the invention. Seeds harvested from a mutant plant that is homozygous for the mlo mutations are preferred.

[0081] In another embodiment, the present invention provides a regenerable mutant plant as described herein cells for use in tissue culture. The tissue culture will preferably be capable of regenerating plants having essentially all of the physiological and morphological characteristics of the foregoing mutant wheat plant, and of regenerating plants having substantially the same genotype. Preferably, the regenerable cells in such tissue cultures will be callus, protoplasts, meristematic cells, cotyledons, hypocotyl, leaves, pollen, embryos, roots, root tips, anthers, pistils, shoots, stems, petiole, flowers, and seeds. Still further, the present invention provides wheat plants regenerated from the tissue cultures of the invention.

[0082] In a preferred embodiment, the mutant wheat plants are produced by simultaneous editing of the target M/o sequences.

[0083] The invention also relates to an isolated nucleic acid sequence as defined in SEQ ID NO. 38 or 39. Also within scope of the invention are vectors comprising such sequences and host cells comprising such sequences or such vector.

Method for Producing Plants

[0084] In another aspect, the invention relates to a method for producing a wheat plant, plant part of plant cell resistant to powdery mildew compared to a wild type wheat plant and comparable yield under non-disease conditions compared to a wild type wheat plant using targeted genome modification comprising introducing a loss of function mutation into the coding regions of two TaMLO alleles selected from TaMLO-A1, TaMLO-B1 and TaMLO-D1 and reducing expression of the third TaMLO allele. For example, a mutation that reduces expression of the third TaMLO allele may be introduced wherein said mutation is not in the coding region of said third TaMLO allele.

[0085] In one embodiment, loss of function mutations are introduced in the coding regions of TaMLO-A1 and TaMLO-D1 and the expression of TaMLO-B1 is reduced.

[0086] The third mutation results in impaired accumulation of the transcript of the third TaMLO allele and/or impaired accumulation of the protein encoded by the third TaMLO allele but is not in the coding region of said third TaMLO allele.

[0087] Plants that have a loss of function mutation in one or two MLO genes according to the invention can be crossed to obtain a loss of function triple mutant. For example, a plant obtained by a method above that has a loss of function mutation in the TaMLO-A1 allele can be crossed with a plant obtained by a method above that has a loss of function mutation in TaMLO-B1 allele or TaMLO-D1 allele. The resulting double mutant can be crossed with another plant obtained by a method above that has mutation which inactivates the remaining allele.

[0088] In one embodiment of the methods described herein, all mutations are introduced simultaneously into the wheat plant using targeted genome modification. Progeny that is homozygous for the mutations can then be generated.

[0089] Targeted genome modification or targeted genome editing is a genome engineering technique that uses targeted DNA double-strand breaks (DSBs) to stimulate genome editing through homologous recombination (HR)-mediated recombination events. To achieve effective genome editing via introduction of site-specific DNA DSBs, four major classes of customizable DNA binding proteins can be used: meganucleases derived from microbial mobile genetic elements, ZF nucleases based on eukaryotic transcription factors, rare-cutting endonucleases, for example TALENs, transcription activator-like effectors (TALEs) from Xanthomonas bacteria, and the RNA-guided DNA endonuclease Cas9 from the type II bacterial adaptive immune system CRISPR (clustered regularly interspaced short palindromic repeats). Meganuclease, ZF, and TALE proteins all recognize specific DNA sequences through protein-DNA interactions. Although meganucleases integrate its nuclease and DNA-binding domains, ZF and TALE proteins consist of individual modules targeting 3 or 1 nucleotides (nt) of DNA, respectively. ZFs and TALEs can be assembled in desired combinations and attached to the nuclease domain of Fokl to direct nucleolytic activity toward specific genomic loci.

[0090] The step of introducing a mutation comprises contacting a population of wheat plant cells with DNA binding protein targeted to endogenous TaMLOA, B and D sequences, for example selected from the DNA binding proteins listed above.

[0091] In one embodiment, the method comprises contacting a population of wheat plant cells with one or more rare-cutting endonucleases targeted to endogenous TaMLO-A, B and D sequences.

[0092] The method may further comprise the steps of selecting, from said population, a cell in which TaMLOA, B and D have been inactivated and regenerating said selected plant cell into a wheat plant.

[0093] Upon delivery into host cells via the bacterial type III secretion system, TAL effectors enter the nucleus, bind to effector-specific sequences in host gene promoters and activate transcription. Their targeting specificity is determined by a central domain of tandem, 33-35 amino acid repeats. This is followed by a single truncated repeat of 20 amino acids. The majority of naturally occurring TAL effectors examined have between 12 and 27 full repeats.

[0094] These repeats only differ from each other by two adjacent amino acids, their repeat-variable di-residue (RVD). The RVD that determines which single nucleotide the TAL effector will recognize: one RVD corresponds to one nucleotide, with the four most common RVDs each preferentially associating with one of the four bases. Naturally occurring recognition sites are uniformly preceded by a T that is required for TAL effector activity. TAL effectors can be fused to the catalytic domain of the Fokl nuclease to create a TAL effector nuclease (TALEN) which makes targeted DNA double-strand breaks (DSBs) in vivo for genome editing. The use of this technology in genome editing is well described in the art, for example in U.S. Pat. No. 8,440,431, U.S. Pat. No. 8,440,432 and U.S. Pat. No. 8,450,471. Reference 30 describes a set of customized plasmids that can be used with the Golden Gate cloning method to assemble multiple DNA fragments. As described therein, the Golden Gate method uses Type IIS restriction endonucleases, which cleave outside their recognition sites to create unique 4 bp overhangs. Cloning is expedited by digesting and ligating in the same reaction mixture because correct assembly eliminates the enzyme recognition site. Assembly of a custom TALEN or TAL effector construct and involves two steps: (i) assembly of repeat modules into intermediary arrays of 1-10 repeats and (ii) joining of the intermediary arrays into a backbone to make the final construct.

[0095] Another genome editing method that can be used according to the various aspects of the invention is CRISPR. The use of this technology in genome editing is well described in the art, for example in U.S. Pat. No. 8,697,359 and references cited herein. In short, CRISPR is a microbial nuclease system involved in defense against invading phages and plasmids. CRISPR loci in microbial hosts contain a combination of CRISPR-associated (Cas) genes as well as non-coding RNA elements capable of programming the specificity of the CRISPR-mediated nucleic acid cleavage (sgRNA). Three types (I-III) of CRISPR systems have been identified across a wide range of bacterial hosts. One key feature of each CRISPR locus is the presence of an array of repetitive sequences (direct repeats) interspaced by short stretches of non-repetitive sequences (spacers). The non-coding CRISPR array is transcribed and cleaved within direct repeats into short crRNAs containing individual spacer sequences, which direct Cas nucleases to the target site (protospacer). The Type II CRISPR is one of the most well characterized systems and carries out targeted DNA double-strand break in four sequential steps. First, two non-coding RNA, the pre-crRNA array and tracrRNA, are transcribed from the CRISPR locus. Second, tracrRNA hybridizes to the repeat regions of the pre-crRNA and mediates the processing of pre-crRNA into mature crRNAs containing individual spacer sequences. Third, the mature crRNA:tracrRNA complex directs Cas9 to the target DNA via Watson-Crick base-pairing between the spacer on the crRNA and the protospacer on the target DNA next to the protospacer adjacent motif (PAM), an additional requirement for target recognition. Finally, Cas9 mediates cleavage of target DNA to create a double-stranded break within the protospacer.

[0096] Cas9 is thus the hallmark protein of the type II CRISPR-Cas system, and a large monomeric DNA nuclease guided to a DNA target sequence adjacent to the PAM (protospacer adjacent motif) sequence motif by a complex of two noncoding RNAs: CRIPSR RNA (crRNA) and trans-activating crRNA (tracrRNA). The Cas9 protein contains two nuclease domains homologous to RuvC and HNH nucleases. The HNH nuclease domain cleaves the complementary DNA strand whereas the RuvC-like domain cleaves the non-complementary strand and, as a result, a blunt cut is introduced in the target DNA. Heterologous expression of Cas9 together with an sgRNA can introduce site-specific double strand breaks (DSBs) into genomic DNA of live cells from various organisms. For applications in eukaryotic organisms, codon optimized versions of Cas9, which is originally from the bacterium Streptococcus pyogenes, have been used.

[0097] The single guide RNA (sgRNA) is the second component of the CRISPR/Cas system that forms a complex with the Cas9 nuclease. sgRNA is a synthetic RNA chimera created by fusing crRNA with tracrRNA. The sgRNA guide sequence located at its 5 end confers DNA target specificity. Therefore, by modifying the guide sequence, it is possible to create sgRNAs with different target specificities. The canonical length of the guide sequence is 20 bp. In plants, sgRNAs have been expressed using plant RNA polymerase III promoters, such as U6 and U3.

[0098] Cas9 expression plasmids for use in the methods of the invention can be constructed as described in the art. One example is provided as described in the example section herein.

[0099] The method for producing a mutant wheat plant according to the invention resistant to Pm using genome editing comprises the use of a SSN. This may be selected from a meganuclease, ZFN, TALEN, or CRISPR/Cas9. In one embodiment, the SSNs is a TALEN.

[0100] Thus, in one embodiment, the method comprises the use of TALEN. In this embodiment, the method comprises introducing an expression vector comprising a TALEN into a wheat plant and screening for TALEN-induced targeted mutations in TaMLO-A1, TaMLO-B1 and/or TaMLO-D1 genes. The method may also comprise the further step of regenerating a plant and selecting or choosing a plant resistant to Pm.

[0101] In one embodiment, said vector comprises a pair of TALENs (T-MLO) targeting a conserved region in exon 2 (FIG. 1a, 9 and table 1). The vector construct encodes a pair of TALENs that targets sequences conserved between all three homoeologues MLO genes of wheat.

[0102] Thus, in one embodiment, the target sequence site in TaMLO is TCGCTGCTGCTCGCCGTgacgcaggaccccatctcCGGGATATGCATCTCCGA (SEQ ID NO. 13, Table 1).

[0103] Specifically, the binding site sequences of the second exon conserved region TaMLO-A, TaMLO-B and TaMLO-D to which these TALENs bind are:

TABLE-US-00002 (SEQIDNO.14) MLO-A:TCGCTGCTGCTCGCCGTcacgcaggacccaatctcCGGGATATG CATCTCCCA (SEQIDNO.15) MLO-B:TCGCTGCTGCTCGCCGTgacgcaggaccccatctcCGGGATATG CATCTCCGA (SEQIDNO.16) MLO-D:TCGCTGCTGCTCGCCGTgacgcaggacccaatctcCGGGATATG CATCTCCGA

[0104] The three SNPs are in bold and underlined. The Avail restriction site is shown in small letters and underlined.

[0105] A TALEN pair has for example the nucleic acid sequence SEQ ID NO. 11. The corresponding amino acid sequence is SEQ ID NO. 12.

[0106] In this embodiment, the TALEN pair recognizes 16 bp and 17 bp, respectively, of contiguous DNA separated by an 18 bp spacer DNA containing an Avail restriction site as shown above, (Table 1). The TALEN recognition sequences are strictly conserved in TaMLO-B1 and TaMLO-D1, but have one nucleotide mismatch with the cognate TaMLO-A1 target site (FIG. 2a). In addition, the conserved spacer region in FIG. 2a contains two single nucleotide polymorphisms (SNPs) among the three MLO homoeo-alleles.

[0107] As shown in the examples, in order to detect the mutation at the site targeted by the genetic editing technique, an Ava II enzyme digestion locus was selected from the targeted sites; if mutation occurred, then the Ava II enzyme digestion locus was damaged and cannot be digested. However, non-mutated PCR products are susceptible to digestion.

[0108] In one embodiment, the TALENs are assembled by the Golden Gate cloning method and built into a single plasmid as described in the examples.

[0109] In one embodiment, screening for TALEN-induced targeted mutations in TaMLO-A1, TaMLO-B1 and TaMLO-D1 genes comprises obtaining a DNA sample from a transformed plant and carrying out DNA amplification and optionally restriction enzyme digestion to detect a mutation in TaMLO-A1, TaMLO-B1 and/or TaMLO-D1. When the target site is as shown above, the restriction enzyme is Avail.

[0110] PCR fragments amplified from the transformed plants are then assessed using a gel electrophoresis based assay. In a further step, the presence of the mutation may be confirmed by sequencing the TaMLO-A1, TaMLO-B1 and/or TaMLO-D1 genes.

[0111] In another embodiment, the method comprises the use of CRISPR/Cas9. In this embodiment, the method therefore comprises introducing and co-expressing in a wheat plant Cas9 and sgRNA targeted to TaMLO-A1, TaMLO-B1 and/or TaMLO-D1 and screening for induced targeted mutations in TaMLO-A1, TaMLO-B1 and TaMLO-D1 genes. The method may also comprise the further step of regenerating a plant and selecting or choosing a plant resistant to Pm.

[0112] Cas9 and sgRNA may be comprises in a single or two expression vectors.

[0113] The target sequence in TaMLO-A1 may be CCGTCACGCAGGACCCAATCTCC (SEQ ID NO. 17, see table 1).

[0114] In one embodiment, screening for CRISPR-induced targeted mutations in TaMLO-A1, TaMLO-B1 and TaMLO-D1 genes comprises obtaining a DNA sample from a transformed plant and carrying out DNA amplification and optionally restriction enzyme digestion to detect a mutation in TaMLO-A1, TaMLO-B1 and/or TaMLO-D1.

[0115] In one embodiment, the restriction enzyme is mismatch-sensitive T7 endonuclease. T7E1 enzyme that is specific to heteroduplex DNA caused by genome editing.

[0116] PCR fragments amplified from the transformed plants are then assessed using a gel electrophoresis assay based assay. In a further step, the presence of the mutation may be confirmed by sequencing the TaMLO-A1, TaMLO-B1 and/or TaMLO-D1 genes.

[0117] As shown in the examples, genomic DNA (i.e. wt and mutant) can be prepared from each sample, and DNA fragments encompassing each target site are amplified by PCR (see Table). The PCR products are digested by restriction enzymes as the target locus includes a restriction enzyme site. The restriction enzyme site is destroyed by CRISPR- or TALEN-induced mutations by NHEJ or HR, thus the mutant amplicons are resistant to restriction enzyme digestion, and result in uncleaved bands. Alternatively, the PCR products are digested by T7E1 (cleaved DNA produced by T7E1 enzyme that is specific to heteroduplex DNA caused by genome editing) and visualized by agarose gel electrophoresis. In a further step, they are sequenced.

[0118] In another aspect, the invention relates to a method for conferring resistance to Pm to a wheat plant, plant part or plant cell comprising introducing a loss of function mutation into the coding region of two MLO alleles selected from TaMLO-A1, TaMLO-B1 and TaMLO-D1 and reducing expression of the third TaMLO allele, for example by introducing a further mutation which results in impaired accumulation of the transcript of the third TaMLO allele and/or impaired accumulation of the protein encoded by the third TaMLO allele wherein said mutation is not in the coding region of the third TaMLO allele wherein said mutations are introduced using targeted genome modification.

[0119] In one embodiment, ZFN, a rare-cutting endonuclease, for example TALEN, or CRISPR/Cas9 is used. In one embodiment, the method comprises producing a mutant plant as described above.

[0120] In the methods above, amplification is preferably carried out using PCR and primers that specifically amplify TaMLO-A1, TaMLO-B1 and TaMLO-D1 (table 2) and as shown below:

[0121] The following primer pair amplifies the TaMLO-A1 target site:

TABLE-US-00003 MLO-A1-F (SEQIDNO.18) TGGCGCTGGTCTTCGCCGTCATGATCATCGTC MLO-A1-R (SEQIDNO.19) TACGATGAGCGCCACCTTGCCCGGGAA

[0122] The following primer pair amplifies the TaMLO-B1 target site:

TABLE-US-00004 MLO-B1-F (SEQIDNO.20) ATAAGCTCGGCCATGTAAGTTCCTTCCCGG MLO-B1-R (SEQIDNO.21) CCGGCCGGAATTTGTTTGTGTTTTTGTT

[0123] The following primer pair amplifies the TaMLO-D1 target site:

TABLE-US-00005 MLO-D1-F (SEQIDNO.22) TGGCTTCCTCTGCTCCCTTGGTGCACCT MLO-D1-R (SEQIDNO.23) TGGAGCTGGTGCAAGCTGCCCGTGGACATT

[0124] The following primer pair amplifies all three alleles

TABLE-US-00006 MLO-F (SEQIDNO.24) GTCTTCGCCGTCATGATCATCGTCTCC MLO-R (SEQIDNO.25) TGGTATTCCAAGGAGGCGGTCTCTGTCT

[0125] In a preferred embodiment, the methods above are carried out by transforming wheat embryos. In a further preferred embodiment, the methods comprise generating stable T2 plants preferably homozygous for the mutation.

[0126] In one embodiment, the methods do not comprise transforming wheat protoplasts.

[0127] The methods above use plant transformation to introduce an expression vector comprise a SSN into a plant. The term introduction or transformation as referred to herein encompasses the transfer of an exogenous polynucleotide into a host cell, irrespective of the method used for transfer. Plant tissue capable of subsequent clonal propagation, whether by organogenesis or embryogenesis, may be transformed with a genetic construct of the present invention and a whole plant regenerated there from. The particular tissue chosen will vary depending on the clonal propagation systems available for, and best suited to, the particular species being transformed. Exemplary tissue targets include leaf disks, pollen, embryos, cotyledons, hypocotyls, megagametophytes, callus tissue, existing meristematic tissue (e.g., apical meristem, axillary buds, and root meristems), and induced meristem tissue (e.g., cotyledon meristem and hypocotyl meristem). The resulting transformed plant cell may then be used to regenerate a transformed plant in a manner known to persons skilled in the art. The transfer of foreign genes into the genome of a plant is called transformation. Transformation of plants is now a routine technique in many species. Advantageously, any of several transformation methods may be used to introduce the gene of interest into a suitable ancestor cell. The methods described for the transformation and regeneration of plants from plant tissues or plant cells may be utilized for transient or for stable transformation. Transformation methods include the use of liposomes, electroporation, chemicals that increase free DNA uptake, injection of the DNA directly into the plant, particle bombardment as described in the examples, transformation using viruses or pollen and microprojection. Methods may be selected from the calcium/polyethylene glycol method for protoplasts, electroporation of protoplasts, microinjection into plant material, DNA or RNA-coated particle bombardment, infection with (non-integrative) viruses and the like. Transgenic plants, including transgenic crop plants, are preferably produced via Agrobacterium tumefaciens mediated transformation.

[0128] To select transformed plants, the plant material obtained in the transformation is, as a rule, subjected to selective conditions so that transformed plants can be distinguished from untransformed plants. For example, the seeds obtained in the above-described manner can be planted and, after an initial growing period, subjected to a suitable selection by spraying. A further possibility is growing the seeds, if appropriate after sterilization, on agar plates using a suitable selection agent so that only the transformed seeds can grow into plants. Alternatively, the transformed plants are screened for the presence of a selectable marker.

[0129] Following DNA transfer and regeneration, putatively transformed plants may also be evaluated, for instance using Southern analysis, for the presence of the gene of interest, copy number and/or genomic organisation. Alternatively or additionally, expression levels of the newly introduced DNA may be monitored using Northern and/or Western analysis, both techniques being well known to persons having ordinary skill in the art.

[0130] The generated transformed plants may be propagated by a variety of means, such as by clonal propagation or classical breeding techniques. For example, a first generation (or T1) transformed plant may be selfed and homozygous second-generation (or T2) transformants selected, and the T2 plants may then further be propagated through classical breeding techniques.

[0131] The SSN is preferably introduced into a plant as part of an expression vector. The vector may contain one or more replication systems which allow it to replicate in host cells. Self-replicating vectors include plasmids, cosmids and virus vectors. Alternatively, the vector may be an integrating vector which allows the integration into the host cell's chromosome of the DNA sequence. The vector desirably also has unique restriction sites for the insertion of DNA sequences. If a vector does not have unique restriction sites it may be modified to introduce or eliminate restriction sites to make it more suitable for further manipulation. Vectors suitable for use in expressing the nucleic acids, are known to the skilled person and a non-limiting example is pYP010.

[0132] The nucleic acid is inserted into the vector such that it is operably linked to a suitable plant active promoter. Suitable plant active promoters for use with the nucleic acids include, but are not limited to CaMV35S, wheat U6, or maize ubiquitin promoters.

[0133] The vector may also comprise a GFP sequence or other marker as explained in the examples and in the figures.

[0134] A plant, plant part or plant cell obtained or obtainable by the methods described above is also within the scope of the invention.

[0135] In one aspect, the mutant is TALEN free. Thus, according to the method above, the presence of a TALEN can be assessed as described in the examples.

[0136] In additional steps, the method may comprise determining the presence of a mutant tamlo-a1, tamlo-b1 and/or tamlo-d1 nucleic acid or detecting the presence or absence of a TaMLO-A, B or D protein in a wheat plant.

[0137] A diagnostic test determining the presence of a mutant tamlo-a1, tamlo-b1 and/or tamlo-d1 nucleic acid may involve hybridisation of a suitable oligo- or poly-nucleotide, such as a fragment of the Mlo gene. The hybridisation may involve PCR designed to amplify a nucleic acid product from a given allelic version of mlo, with subsequent detection of an amplified product by any of a number of possible methods including but not limited to gel electrophoresis, capillary electrophoresis and direct hybridisation of nucleotide sequence probes. A diagnostic test may be based on PCR designed to amplify various mutant nucleic acids from the Mlo locus, with a test to distinguish the different possible mutant nucleic acids from the wild type by any of a number of possible methods, including DNA fragment size, restriction site variation (e.g. CAPS-cleaved amplified polymorphic sites) and so on. A diagnostic test may also be based on a great number of possible variants of nucleic acid analysis that will be apparent to those skilled in the art, such as use of a synthetic mlo-derived sequence as a hybridisation probe.

[0138] Suitable tests for assessing the presence of a mutant allele according to the invention include but are not limited to among these are Isozyme Electrophoresis, Restriction Fragment Length Polymorphisms (RFLPs), Randomly Amplified Polymorphic DNAs (RAPDs), Arbitrarily Primed Polymerase Chain Reaction (AP-PCR), DNA Amplification Fingerprinting (DAF), Sequence Characterized Amplified Regions (SCARs), Amplified Fragment Length polymorphisms (AFLPs), Simple Sequence Repeats (SSRs-which are also referred to as Microsatellites), and Single Nucleotide Polymorphisms (SNPs). In one embodiment, Kompetitive Allele Specific PCR (KASP) genotyping is used. In one embodiment, the method comprises [0139] a) obtaining a nucleic acid sample from a wheat plant and [0140] b) carrying out nucleic acid amplification of one or more TaMLO allele using one or more primer pairs selected from SEQ ID NOs 18 to 25 or SEQ ID NOs. 34-37.

TABLE-US-00007 MLO-R32-A1-F: SEQIDNO.34 TGATGATGATGATGATGGAACTTGTTCTCG MLO-R32-A1-R: SEQIDNO.35 AAGGAGGCGGTCTCTGTCTCCCATTTCTTC MLO-R32-D1-F: SEQIDNO.36 TTCATCTCGCTGCTGCTCCATCTCCG MLO-R32-D1-R: SEQIDNO.37 AGCCATGATGATGACGCTGTAGGTGACATG

[0141] In one embodiment, the method comprises determining whether a TaMLO protein accumulates in the plant. Thus, the presence or absence of a TaMLO-A, B or D protein in a plant is detected. If the protein is absent, a mutation which impairs protein accumulation is present in the genome of the plant. In one embodiment, the presence or absence of a TaMLO-B protein in a plant is detected.

[0142] Suitable tests for assessing the presence of a protein are known in the art and include, but are not limited to, Gel Electrophoresis (such as Polyacrylamide Protein Gel Electrophoresis or 2D Gel Electrophoresis), colorimetric assays, Western Blotting, Immunoassays (such as ELISA, lateral flow strips or immunostaining) or spectrophotometry.

[0143] The invention also relates to an isolated nucleic acid sequence comprising one or more primer selected from SEQ ID NOs. 34-37. The invention also relates to a detection kit comprising one or more primer selected from SEQ ID NOs. 34-37.

[0144] The various aspects of the invention described herein clearly extend to any plant cell or any plant produced, obtained or obtainable by any of the methods described herein, and to all plant parts and propagules thereof unless otherwise specified. The present invention extends further to encompass the progeny of a mutant plant cell, tissue, organ or whole plant that has been produced by any of the aforementioned methods, the only requirement being that progeny exhibit the same genotypic and/or phenotypic characteristic(s) as those produced by the parent in the methods according to the invention.

[0145] While the foregoing disclosure provides a general description of the subject matter encompassed within the scope of the present invention, including methods, as well as the best mode thereof, of making and using this invention, the following examples are provided to further enable those skilled in the art to practice this invention and to provide a complete written description thereof. However, those skilled in the art will appreciate that the specifics of these examples should not be read as limiting on the invention, the scope of which should be apprehended from the claims and equivalents thereof appended to this disclosure. Various further aspects and embodiments of the present invention will be apparent to those skilled in the art in view of the present disclosure.

[0146] All documents mentioned in this specification, including reference to sequence database identifiers, are incorporated herein by reference in their entirety. Unless otherwise specified, when reference to sequence database identifiers is made, the version number is 1.

[0147] and/or where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. For example A and/or B is to be taken as specific disclosure of each of (i) A, (ii) B and (iii) A and B, just as if each is set out individually herein.

[0148] Unless context dictates otherwise, the descriptions and definitions of the features set out above are not limited to any particular aspect or embodiment of the invention and apply equally to all aspects and embodiments which are described.

[0149] The invention is further described in the following non-limiting examples.

EXAMPLES

Talen Design and Construction

[0150] TALEN target sites were designed using the TAL effector-Nucleotide Targeter 2.0 (TALE-NT) program (https://tale-nt.cac.cornell.edu/). All the target sites had a T at the 1 position, and the corresponding TAL effector arrays were constructed using the Golden Gate method as previously described.sup.33. Information on all the TAL effecter arrays and target sites is given in Table 1. TALENs were assembled in vectors with a truncated N152/C63 backbone architecture (pZHY500 and pZHY501). The Gateway-compatible entry plasmid, pZHY013, was used as the intermediate vector to create TALEN expression vectors.sup.34. This plasmid contains two heterodimeric Fokl nuclease domains separated by a T2A translational skipping sequence. TAL arrays in the plasmids pZHY500 and pZHY501 were released by digestion with XbaI/BamHI and subcloned into pZHY013 one-by-one.sup.34,35. One array (left array) was first cloned into pZHY013 as an XbaI/BamHI fragment; the other (right array) was then cloned into the NheI/BgIII sites, which have ends compatible with XbaI and BamHI. A Gateway LR reaction was performed to clone the TALEN coding sequences into the destination vector, pYPO10 (a derivative of pZHY05134 by replacing the 35S promoter with the maize ubiquitin promoter.

Construction of Cas9 and sgRNA Expression Vectors

[0151] The plasmid pJIT163 was used to construct the Cas9 expression plasmid. It was digested with KpnI and HindIII and fused with the maize ubiquitin 1 promoter (Ubi) to construct vector pJIT163-Ubi. Full-length Cas9 (plant codon-optimized) products were digested with BamHI and MfeI and inserted into plasmid pJIT163-Ubi between the BamHI and MfeI sites to yield the expression vector pJIT163-Ubi-Cas9. The wheat U6 promoters and wheat gRNA scaffolds were synthesized by GenScript and cloned into pEASY-blunt vector (TransGen Biotech). The sequences of Cas9 and the gRNAs are given in a previous publication.sup.17. Wheat genomic DNA region immediately precede a 5-NGG PAM, such as 5-G-N(20)-GG-3 or 5-N(21)-GG-3 was selected as target.

[0152] The CRISPR/Cas9 target site in TaMLO contains two single nucleotide polymorphisms (SNPs) among the three homoeoalleles. We designed a sgRNA (sgMLO-A1) to specifically target TaMLO-A. Our results show that sgRNA-A1-induced mutations only occurred in TaMLO-A1, so confirming the specificity of the sgRNA for TaMLO-A1. Therefore, off-target cleavage did not occur in TaMLO-B1 and TaMLO-D1. The results show that CRISPR/Cas9 is active in wheat plants and that transgenic mutant lines can be generated. Other mutants, including a triple mutant AA, BB and DD can be obtained using Cas9/sgRNA by targeting a conserved target site.

Wheat Protoplast Transformation

[0153] Wheat protoplasts were isolated and transformed as previously described.sup.3. Average transformation efficiencies were 60-80%. Protoplast transformation was carried out with 20 g of TALEN plasmid per transformation, or a mixture of 10 g pJIT163-Ubi-Cas9 plasmid and 10 g pU6-gRNA plasmid.

Biolistic Transformation of Wheat

[0154] Biolistic transformation was performed using a PDS1000/He particle bombardment system (Bio-Rad, Hercules, Calif.) with a target distance of 6.0 cm from the stopping plate at helium pressure 1100 psi. Plasmid DNAs (T-MLO and pAHC20) were mixed in a 1:1 (1:1:1 for Cas9, sgRNA and pAHC20) molar ratio prior to bombardment. After bombardment, embryos were transferred to callus induction medium. In the third or fourth week, all calli were transferred to selective regeneration medium containing 5 mg/I phosphinothricin (PPT). PPT was present in all subsequent tissue culture procedures including 2 rounds of regeneration (4 weeks) and 2 rounds of rooting (4 weeks). After 10-12 weeks, T0 transgenic plants were obtained, transferred into soil and grown in a management greenhouse.sup.37.

Screening of SSN-Induced Mutations

[0155] Genomic DNA from individual wheat plants was extracted using the high-throughput Automation Workstation Biomek FX (Beckmen) with the magnetic bead-based DNA extraction kit (GeneOn Biotech). The PCR/RE digestion screen assay and T7E1 assay were used to identify the mutations as previously described.sup.35, 36, 37. The PCR products amplified with TaMLO-specific primers (Table 3) from individual mutant plants were cloned into pUC-T vector (CWBIO) for sequencing. Mutation frequencies (indels (%)) in protoplasts were calculated by measuring band intensities with UVP VisionWorks LS Image Acquisition Analysis Software 7.0.sup.36.

Powdery Mildew Infection and Microscopic Analyses

[0156] Wheat plants were grown on soil in controlled environment chambers at 22 C. and 16-h photoperiod with light intensity ranging from 400-1,000 mol m.sup.2 s.sup.1. Powdery mildew infection and microscopic analyses were performed as previously reported.sup.39 with some modifications. Leaves originating from the main stem (leaves 2, 3, and 4) were cut into 5 cm segments and immediately placed in Petri dishes containing 1% (w/v) distilled water agar and 8.5 mM benzimidazole. The leaf segments were incubated at 22 C. in continuous light (100 mol m.sup.2 s.sup.1) for four hour, then inoculated with virulent strains of Blumeria graminis f. sp. tritici (Bgt) E09, E22 and B13 to give approximately 15 to 20 sporulating colonies per cm.sup.2 and incubated at 22 C. in continuous light (100 umol m.sup.2 s.sup.1). Seventy-two hours after inoculation, the leaf segments were fixed with 1:1 (v/v) ethanol: acetic acid for 24 h, cleared with lactoglycerol (1:1:1 [v/v] lactic acid:glycerol:H2O) for 48 h, and stained for 7 sec with Coomassie blue (0.6% [w/v] Coomassie Brilliant Blue R 250 [Sigma] in methanol) to visualize the fungal structure, finally rinsed in distilled water and mounted in 50% (v/v) glycerol prior to microscopy. Samples were observed and analyzed under an Olympus BX51light microscope, and photographs were taken using software Cellsens Entry 1.21.

Yield Index Test for Mlo Mutants

[0157] Plants were grown in a standard wheat field in 2010 cm plots (20 plants) under conventional cultivation conditions. There was no powdery mildew disease in the field and no fungicide was used. All phenotypical data including thousand seed weight (TKW), seed circumference, seed length and seed width were measured. Data were from 9 replicates for the mutant R32 and wildtype control (Bobwhite), 8 replicates for the mutat mlo-aabbdd and wildtype control (Kn199), respectively.

[0158] About 400 filled grains of mutant lines and wildtype plants of one 5-plant sample in every replicate were picked for TKW measurements using Electron balance. About 150 filled mutants and wildtype grains of one treatment in every sample were used to measure the seed circumference, seed length and seed width by Wanshen kaozhong examination analyzer.

Results and Discussion

[0159] We deployed a pair of TALENs (T-MLO) targeting a conserved region in exon 2 (FIG. 2a). The TALEN pair recognizes 16 bp and 17 bp, respectively, of contiguous DNA separated by an 18 bp spacer DNA containing an Avail restriction site (FIG. 1a and Table 1). The TALEN recognition sequences are strictly conserved in TaMLO-B1 and TaMLO-D1, but have one nucleotide mismatch with the cognate TaMLO-A1 target site (FIG. 2a). In addition, the conserved spacer region in FIG. 2a contains two single nucleotide polymorphisms (SNPs) among the three MLO homoeo-alleles. The TALENs were assembled by the Golden Gate cloning method.sup.30, and built into a single plasmid by a T2A translational skipping sequence driven by the maize ubiquitin promoter. The activity of the resulting T-MLO was first evaluated by transforming the TALEN-carrying plasmid into wheat protoplasts. Analysis of genomic DNA from the transformed protoplasts using a previously developed PCR restriction enzyme digestion assay (PCR/RE).sup.16 demonstrated the occurrence of mutations at the target site.

[0160] We then co-transformed the T-MLO plasmid and pAHC20.sup.31, a plasmid harboring the selectable bar gene, into immature wheat embryos by the particle bombardment method. Wheat seedlings were regenerated from herbicide-resistant calli after 6-8 weeks of selection on 5 g/ml phosphinothricin (PPT). The MLO target sites (in TaMLO-A1, TaMLO-B1 and TaMLO-D1) were first amplified from the genomic DNA of these transgenic seedlings (T0 plants) using a conserved primer set (Table 2), and analyzed by the PCR/RE assay to detect potential mutations. In order to identify in which of the TaMLO genes the mutations occurred, we designed primers to specifically amplify TaMLO-A1, TaMLO-B1 and TaMLO-D1 and conducted PCR/RE assays of the PCR amplicons with the specific primers (Table 2). This revealed the revealed that T-MLO-induced mutations as shown in FIG. 1.

[0161] We identified Tamlo-R (with genetic profile tamlo-AaBBDd), which is heterozygous in genome A and D, but no mutation was identified at the target site in genome B in T0 plants (FIG. 2). After segregation, in T1 generation, we identified 7 plants homozygous for the mutation in genome A and D (tamlo-aaBBdd), named as R4, R25, R26, R32, R40, R51 and R54. When all the 7 homozygous T1 plants were challenged with conidiospores of a virulent Bgt race, we found that only the homozygous plant R32 confers resistance to powdery mildew (FIG. 2). Interestingly, R32 did not display the senescence-like chlorosis, and the plant grew as vigorously as the wild type.

[0162] To confirm this view, we tested the thousand kernel weight (TKW) for the R32 mutant and wild type plant in the yield. The results showed that the R32 (which is in Bobwhite background) has significantly elevated thousand kernel weight (TKW) compared with wildtype in Bobwhite WT control (P<0.01), but there was no such difference between the mlo-aabbdd mutant (in Kn199 background) and Kn199 WT control (FIG. 8A and FIG. 9A). Moreover, there is no obvious change in other parameters including seed circumference, seed length and seed width between mutant (R32 and mlo-aabbdd) and wildtype both in Bobwhite and Kn199 (FIGS. 8 and 9).

[0163] We also assessed the resistance to powdery mildew of offspring of all the homozygous mutant progeny of line Tamlo-R (R4, R25, R26, R32, R40, R51 and R54). We found that all the progeny of R32 showed resistance to Bgt, and about of R26, R40 and R54 offspring were resistant to the Bgt. All the progeny of R51 were susceptible to the Bgt (FIG. 3). In contrast to fully resistant mutant tamlo-aabbdd plants, the resistant mutant plants allow the low-level growth of sporulating Bgh (FIG. 3).

[0164] We assessed the level of transcription of mlo for these mutants in genome A, B and D, respectively. We find that the transcription of the TaMLO protein of genome B (TaMLO-B1) of these resistant plants was lower compared with wild type (FIG. 4).

[0165] To date, race-specific resistance controlled by the resistance (R) gene is commonly used for developing resistant wheat varieties, but this tends to break down as new Bgt races emerge in the field.sup.32. In contrast, loss-of-function mlo mutation-conferred resistance against powdery mildew has not been broken since its introgression into elite barley varieties three decades ago.sup.25. Therefore, the mlo-aaBBdd alleles we generated in the elite wheat cultivars may provide excellent starting materials for breeding durable and broad-spectrum resistance in bread wheat.

Genetic Mapping

[0166] Genetic mapping as shown in FIG. 7 is being carried out.

TABLE-US-00008 TABLE1 SSNtargetlociandsequences LeftBindingSite RightBindingSite Gene RVDs/Oligo-F RVDs/Oligo-R Detection Name SSNID TargetSite (5-3) (5-3) method TaMLO T-MLO TCGCTGCTGCTCGC HDNNHDNGNN HDNNNNNI PCR/RE: CGTgacgcaggaccccatctc HDNGNNHDNG NNNINGNN AvaII CGGGATATGCATCT HDNNHDHDNN HDNINGNING CCGASEQIDNO.13 NGSEQIDNO.49 HDHDHDNN SEQIDNO.50 TaMLO- sgMLO- CCGTCACGCAGGAC CTTGGAGATTGGG AAACTCACGCAG T7E1 A1 A1 CCAATCTCCSEQID TCCTGCGTGASEQ GACCCAATCTC No.17 IDNo.26 SEQIDNo.27

TABLE-US-00009 TABLE2 PCRprimersusedandtheirapplications Primer name Primersequence Experiment MLO-A1- TGGCGCTGGTCTTCGCCGTCATGATCATCGTC Genespecificprimeramplifyingthe F SEQIDNo.18 TaMLO-A1targetsite MLO-A1- TACGATGAGCGCCACCTTGCCCGGGAA R SEQIDNo.19 MLO-B1- ATAAGCTCGGCCATGTAAGTTCCTTCCCGG Genespecificprimeramplifyingthe F SEQIDNo.20 TaMLO-B1targetsite MLO-B1- CCGGCCGGAATTTGTTTGTGTTTTTGTT R SEQIDNo.21 MLO-D1- TGGCTTCCTCTGCTCCCTTGGTGCACCT Genespecificprimeramplifyingthe F SEQIDNo.22 TaMLO-D1targetsite MLO-D1- TGGAGCTGGTGCAAGCTGCCCGTGGACATT R SEQIDNo.23 MLO-F GTCTTCGCCGTCATGATCATCGTCTCC AmplifyingtheTaMLOtargetsite: SEQIDNo.24 Thisprimercanbeusedtoamplify MLO-R TGGTATTCCAAGGAGGCGGTCTCTGTCT allthreealleles SEQIDNo.25 F1 GTCTTCGCCGTCATGATCATCGTCTCCSEQID DetectingNHEJ-mediatedGFP No.28 inserts R1 GGTGCTCAGGTAGTGGTTGTCSEQIDNo.29 F2 CTTTGTCGTGAATATAAACCAGACACGAG DetectingNHEJ-mediatedGFP SEQIDNo.30 inserts R2 TGGTATTCCAAGGAGGCGGTCTCTGTCTSEQ IDNo.31 Ubi-F CAGTTAGACATGGTCTAAAGGACAATTGAG DetectingtheabsenceofTALENs SEQIDNo.32 Ubi-R CCAACCACACCACATCATCACAACCAASEQ IDNo.33

REFERENCES

[0167] All references are incorporated herein by reference. [0168] 1. Voytas, D. F. Plant genome engineering with sequence-specific nucleases. Annu. Rev. Plant. Biol. 64, 327-350 (2013). [0169] 2. Bogdanove, A. J. & Voytas, D. F. TAL effectors: customizable proteins for DNA pargeting. Science 333, 1843-1846 (2011). [0170] 3. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821 (2012). [0171] 4. Vrallyay, ., Giczey, G. & Burgyn, J. Virus-induced gene silencing of Mlo genes induces powdery mildew resistance in Triticum aestivum. Arch. Virol. 157, 1345-1350 (2012). [0172] 5. Slade, A. J. et al. A reverse genetic, nontransgenic approach to wheat crop improvement by TILLING. Nat. Biotechnol. 23, 75-81 (2005). [0173] 6. Dvoik, J. in Genetics and Genomics of the Triticeae, Vol. 7. (eds. G. J. Muehlbauer & C. Feuillet) 685-711 (Springer US, 2009). [0174] 7. Bibikova, M., Beumer, K., Trautman, J. K. & Carroll, D. Enhancing gene targeting with designed zinc finger nucleases. Science 300, 764 (2003). [0175] 8. Gorbunova, V. & Levy, A. A. Non-homologous DNA end joining in plant cells is associated with deletions and filler DNA insertions. Nucleic Acids Res. 25, 4650-4657 (1997). [0176] 9. Puchta, H., Dujon, B. & Hohn, B. Homologous recombination in plant cells is enhanced by in vivo induction of double strand breaks into DNA by a site-specific endonuclease. Nucleic Acids Res. 21, 5034-5040 (1993). [0177] 10. Zhang, F. et al. High frequency targeted mutagenesis in Arabidopsis thaliana using zinc-finger nucleases. Proc. Nat.l Acad. Sci. 107, 12028-12033 (2010). [0178] 11. Feng, Z. et al. Multigeneration analysis reveals the inheritance, specificity, and patterns of CRISPR/Cas-induced gene modifications in Arabidopsis. Proc. Nat.l Acad. Sci. doi:10.1073/pnas.1400822111 (2014). [0179] 12. Zhang, Y. et al. Transcription activator-like effector nucleases enable efficient plant genome engineering. Plant physiol. 161, 20-27 (2013). [0180] 13. Wendt, T. et al. TAL effector nucleases induce mutations at a pre-selected location in the genome of primary barley transformants. Plant Mol. Biol. 83, 279-285 (2013). [0181] 14. Gurushidze, M. et al. True-breeding targeted gene knock-out in barley using designer TALE-nuclease in haploid cells. PloS one 9, e92046. doi:10.1371/journal.pone.0092046 (2014). [0182] 15. Curtin, S. J. et al. Targeted mutagenesis of duplicated genes in soybean with zinc-finger nucleases. Plant physiol. 156, 466-473 (2011). [0183] 16. Shan, Q. et al. Rapid and efficient gene modification in rice and brachypodium using TALENs. Mol. Plant 6, 1365-1368 (2013). [0184] 17. Shan, Q. et al. Targeted genome modification of crop plants using a CRISPR-Cas system. Nat. Biotechnol. 31, 686-688 (2013). [0185] 18. Li, T. et al. High-efficiency TALEN-based gene editing produces disease-resistant rice. Nat. Biotechnol. 30, 390-392 (2012). [0186] 19. Feng, Z. et al. Efficient genome editing in plants using a CRISPR/Cas system. Cell Res. 23, 1229-1232 (2013). [0187] 20. Miao, J. et al. Targeted mutagenesis in rice using CRISPR-Cas system. Cell Res. 23, 1233-1236 (2013). [0188] 21. Xie, K. & Yang, Y. RNA-guided genome editing in plants using a CRISPR-Cas system. Mol. Plant. doi:10.1093/mp/sst119 (2013). [0189] 22. Shukla, V. K. et al. Precise genome modification in the crop species Zea mays using zinc-finger nucleases. Nature 459, 437-441 (2009). [0190] 23. Liang, Z., Zhang, K., Chen, K. & Gao, C. Targeted mutagenesis in zea mays using TALENs and the CRISPR/Cas system. J. Genet. Genomics 41, 63-68 (2014). [0191] 24. Christian, M., Qi, Y., Zhang, Y. & Voytas, D. F. Targeted mutagenesis of Arabidopsis thaliana using engineered TAL effector nucleases. G3 (Bethesda) 3, 1697-1705 (2013). [0192] 25. Bschges, R. et al. The barley Mlo gene: A novel control element of plant pathogen resistance. Cell 88, 695-705 (1997). [0193] 26. Piffanelli, P. et al. A barley cultivation-associated polymorphism conveys resistance to powdery mildew. Nature 430, 887-891 (2004). [0194] 27. Consonni, C. et al. Conserved requirement for a plant host cell protein in powdery mildew pathogenesis. Nat. Genet. 38, 716-720 (2006). [0195] 28. Bai, Y. et al. Naturally occurring broad-spectrum powdery mildew resistance in a central american tomato accession is caused by loss of mlo function. Mol. Plant Microbe In. 21, 30-39 (2007). [0196] 29. Elliott, C. et al. Functional conservation of wheat and rice Mlo orthologs in defense modulation to the powdery mildew fungus. Mol. Plant Microbe In. 15, 1069-1077 (2002). [0197] 30. Cermak, T. et al. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res. 39 (2011). [0198] 31. Christensen, A. & Quail, P. Ubiquitin promoter-based vectors for high-level expression of selectable and/or screenable marker genes in monocotyledonous plants. Transgenic. Res. 5, 213-218 (1996). [0199] 32. McDonald, B. A. & Linde, C. Pathogen population genetics, evolutionary potential, and durable resistance. Annu. Re. Phytopathol. 40, 349-379 (2002). [0200] 33. Cermak, T. et al. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res. 39, 1-11 (2011). [0201] 34. Zhang, Y. et al. Transcription activator-like effector nucleases enable efficient plant 50 genome engineering. Plant physiol. 161, 20-27 (2013). [0202] 35. Shan, Q. et al. Rapid and efficient gene modification in rice and brachypodium using TALENs. Mol. Plant 6, 1365-1368 (2013). [0203] 36. Shan, Q. et al. Targeted genome modification of crop plants using a CRISPR-Cas system. Nat. Biotechnol. 31, 686-688 (2013). [0204] 37. Rasco-Gaunt, S. et al. Procedures allowing the transformation of a range of European elite wheat (Triticum aestivum L.) varieties via particle bombardment. J. Exp Bot. 52, 865-874 (2001). [0205] 38. Xie, K. & Yang, Y. RNA-guided genome editing in plants using a CRISPR-Cas system. Molecular plant 6, 1975-1983 (2013). [0206] 39. Hein, I. et al. Virus-induced gene silencing-based functional characterization of genes associated with powdery mildew resistance in barley. Plant physiol. 138, 2155-2164 (2005). [0207] 40. Acevedo-Garcia et al: magical Mystery tour: MLO proteins in plant immunity and beyond. New Phytologist. 1-9 (2014) [0208] 41. Hsu et al: Development and Applications of CRISPR-Cas9 for Genome Engineering. Cell 157, 1262-1278, 2014 [0209] 42. Pifanelli et al A barley cultivation-associated polymorphism conveys resistance to powdery mildew. Nature, Vol. 430, 887-891, 2004 [0210] 43. Wang et al: Simultaneous editing of three homoeoalleles in hexaploid wheat confers heritable resistance to powdery mildew virus. Nature biotehcnology. September; 32(9):947-51, 2014 [0211] 44. Consonni, C. et al. Conserved requirement for a plant host cell protein in powdery mildew pathogenesis. Nat. Genet. 38, 716-720 (2006).

Sequence Information

[0212] SEQ ID NO. 1 Coding sequence of wild type TaMLO-A1:1605 bp; The TALEN target site is indicated underlined.

TABLE-US-00010 ATGGCGGAGGACGACGGGTACCCCCCGGCGCGGACGCTGCCGGAGACGCC GTCCTGGGCGGTGGCGCTGGTCTTCGCCGTCATGATCATCGTCTCCGTCC TCCTGGAGCACGCGCTCCACAAGCTCGGCCAGTGGTTCCACAAGCGGCAC AAGAACGCGCTGGCGGAGGCGCTGGAGAAGATGAAGGCGGAGCTGATGCT GGTGGGATTCATCTCGCTGCTGCTCGCCGTCACGCAGGACCCAATCTCCG GGATATGCATCTCCCAGAAGGCCGCCAGCATCATGCGCCCCTGCAAGGTG GAACCCGGTTCCGTCAAGAGCAAGTACAAGGACTACTACTGCGCCAAAGA GGGCAAGGTGGCGCTCATGTCCACGGGCAGCCTGCACCAGCTCCACATAT TCATCTTCGTGCTAGCCGTCTTCCATGTCACCTACAGCGTCATCATCATG GCTCTAAGCCGTCTCAAGATGAGAACATGGAAGAAATGGGAGACAGAGAC CGCCTCCTTGGAATACCAGTTCGCAAATGATCCTGCGCGGTTCCGCTTCA CGCACCAGACGTCGTTCGTGAAGCGGCACCTGGGCCTGTCCAGCACCCCC GGCGTCAGATGGGTGGTGGCCTTCTTCAGGCAGTTCTTCAGGTCGGTCAC CAAGGTGGACTACCTCACCTTGAGGGCAGGCTTCATCAACGCGCACTTGT CGCAGAACAGCAAGTTCGACTTCCACAAGTACATCAAGAGGTCCATGGAG GACGACTTCAAAGTCGTCGTTGGCATCAGCCTCCCGCTGTGGGCTGTGGC GATCCTCACCCTCTTCCTTGATATCGACGGGATCGGCACACTCACCTGGG TTTCTTTCATCCCTCTCATCATCCTCTTGTGTGTTGGAACCAAGCTAGAG ATGATCATCATGGAGATGGCCCTGGAGATCCAGGACCGGTCGAGCGTCAT CAAGGGGGCACCCGTGGTCGAGCCCAGCAACAAGTTCTTCTGGTTCCACC GCCCCGACTGGGTCCTCTTCTTCATACACCTGACGCTGTTCCAGAACGCG TTTCAGATGGCACATTTCGTGTGGACAGTGGCCACGCCCGGCTTGAAGGA CTGCTTCCATATGAACATCGGGCTGAGCATCATGAAGGTCGTGCTGGGGC TGGCTCTCCAGTTCCTGTGCAGCTACATCACCTTCCCCCTCTACGCGCTA GTCACACAGATGGGATCAAACATGAAGAGGTCCATCTTCGACGAGCAGAC AGCCAAGGCGCTGACCAACTGGCGGAACACGGCCAAGGAGAAGAAGAAGG TCCGAGACACGGACATGCTGATGGCGCAGATGATCGGCGACGCAACACCC AGCCGAGGCACGTCCCCGATGCCTAGCCGGGGCTCATCGCCGGTGCACCT GCTTCAGAAGGGCATGGGACGGTCTGACGATCCCCAGAGCGCACCGACCT CGCCAAGGACCATGGAGGAGGCTAGGGACATGTACCCGGTTGTGGTGGCG CATCCTGTACACAGACTAAATCCTGCTGACAGGAGAAGGTCGGTCTCTTC ATCAGCCCTCGATGCCGACATCCCCAGCGCAGATTTTTCCTTCAGCCAGG GATGA

[0213] SEQ ID NO. 2 Coding sequence of wild type TaMLO-B1:1605 bp; The TALEN target site is indicated underlined.

TABLE-US-00011 ATGGCGGAGGACGACGGGTACCCCCCAGCGAGGACGCTGCCGGAGACGCC GTCCTGGGCGGTGGCCCTCGTCTTCGCCGTCATGATCATCGTGTCCGTCC TCCTGGAGCACGCGCTCCATAAGCTCGGCCAGTGGTTCCACAAGCGGCAC AAGAACGCGCTGGCGGAGGCGCTGGAGAAGATCAAGGCGGAGCTCATGCT GGTGGGCTTCATCTCGCTGCTGCTCGCCGTGACGCAGGACCCCATCTCCG GGATATGCATCTCCGAGAAGGCCGCCAGCATCATGCGGCCCTGCAAGCTG CCCCCTGGCTCCGTCAAGAGCAAGTACAAAGACTACTACTGCGCCAAACA GGGCAAGGTGTCGCTCATGTCCACGGGCAGCTTGCACCAGCTGCACATAT TCATCTTCGTGCTCGCCGTCTTCCATGTCACCTACAGCGTCATCATCATG GCTCTAAGCCGTCTCAAGATGAGAACCTGGAAGAAATGGGAGACAGAGAC CGCCTCCCTGGAATACCAGTTCGCAAATGATCCTGCGCGGTTCCGCTTCA CGCACCAGACGTCGTTCGTGAAGCGGCACCTGGGCCTCTCCAGCACCCCC GGCGTCAGATGGGTGGTGGCCTTCTTCAGGCAGTTCTTCAGGTCGGTCAC CAAGGTGGACTACCTCACCTTGAGGGCAGGCTTCATCAACGCGCATTTGT CGCATAACAGCAAGTTCGACTTCCACAAGTACATCAAGAGGTCCATGGAG GACGACTTCAAAGTCGTCGTTGGCATCAGCCTCCCGCTGTGGTGTGTGGC GATCCTCACCCTCTTCCTTGACATTGACGGGATCGGCACGCTCACCTGGA TTTCTTTCATCCCTCTCGTCATCCTCTTGTGTGTTGGAACCAAGCTGGAG ATGATCATCATGGAGATGGCCCTGGAGATCCAGGACCGGGCGAGCGTCAT CAAGGGGGCGCCCGTGGTTGAGCCCAGCAACAAGTTCTTCTGGTTCCACC GCCCCGACTGGGTCCTCTTCTTCATACACCTGACGCTATTCCAGAACGCG TTTCAGATGGCACATTTCGTGTGGACAGTGGCCACGCCCGGCTTGAAGAA ATGCTTCCATATGCACATCGGGCTGAGCATCATGAAGGTCGTGCTGGGGC TGGCTCTTCAGTTCCTCTGCAGCTATATCACCTTCCCGCTCTACGCGCTC GTCACACAGATGGGATCAAACATGAAGAGGTCCATCTTCGACGAGCAGAC GGCCAAGGCGCTGACAAACTGGCGGAACACGGCCAAGGAGAAGAAGAAGG TCCGAGACACGGACATGCTGATGGCGCAGATGATCGGCGACGCGACGCCC AGCCGAGGGGCGTCGCCCATGCCTAGCCGGGGCTCGTCGCCAGTGCACCT GCTTCACAAGGGCATGGGACGGTCCGACGATCCCCAGAGCACGCCAACCT CGCCAAGGGCCATGGAGGAGGCTAGGGACATGTACCCGGTTGTGGTGGCG CATCCAGTGCACAGACTAAATCCTGCTGACAGGAGAAGGTCGGTCTCGTC GTCGGCACTCGATGTCGACATTCCCAGCGCAGATTTTTCCTTCAGCCAGG GATGA

[0214] SEQ ID NO. 3 Coding sequence of wild type TaMLO-D1:1605 bp; The TALEN target site is indicated underlined.

TABLE-US-00012 ATGGCGGAGGACGACGGGTACCCCCCGGCGCGGACGCTGCCGGAGACGCC GTCCTGGGCGGTGGCGCTCGTCTTCGCCGTCATGATCATCGTGTCCGTCC TCCTGGAGCACGCGCTCCACAAGCTCGGCCAGTGGTTCCACAAGCGGCAC AAGAACGCGCTGGCGGAGGCGCTGGAGAAGATCAAAGCGGAGCTGATGCT GGTGGGGTTCATCTCGCTGCTGCTCGCCGTGACGCAGGACCCAATCTCCG GGATATGCATCTCCGAGAAGGCCGCCAGCATCATGCGGCCCTGCAGCCTG CCCCCTGGTTCCGTCAAGAGCAAGTACAAAGACTACTACTGCGCCAAAAA GGGCAAGGTGTCGCTAATGTCCACGGGCAGCTTGCACCAGCTCCACATAT TCATCTTCGTGCTCGCCGTCTTCCATGTCACCTACAGCGTCATCATCATG GCTCTAAGCCGTCTCAAGATGAGGACATGGAAGAAATGGGAGACAGAGAC CGCCTCCTTGGAATACCAGTTCGCAAATGATCCTGCGCGGTTCCGCTTCA CGCACCAGACGTCGTTCGTGAAGCGTCACCTGGGCCTCTCCAGCACCCCC GGCATCAGATGGGTGGTGGCCTTCTTCAGGCAGTTCTTCAGGTCGGTCAC CAAGGTGGACTACCTCACCCTGAGGGCAGGCTTCATCAACGCGCATTTGT CGCATAACAGCAAGTTCGACTTCCACAAGTACATCAAGAGGTCCATGGAG GACGACTTCAAAGTCGTCGTTGGCATCAGCCTCCCGCTGTGGTGTGTGGC GATCCTCACCCTCTTCCTTGATATTGACGGGATCGGCACGCTCACCTGGA TTTCTTTCATCCCTCTCGTCATCCTCTTGTGTGTTGGAACCAAGCTGGAG ATGATCATCATGGAGATGGCCCTGGAGATCCAGGACCGGGCGAGCGTCAT CAAGGGGGCGCCCGTGGTTGAGCCCAGCAACAAGTTCTTCTGGTTCCACC GCCCCGACTGGGTCCTCTTCTTCATACACCTGACGCTGTTCCAGAATGCG TTTCAGATGGCACATTTCGTCTGGACAGTGGCCACGCCCGGCTTGAAGAA ATGCTTCCATATGCACATCGGGCTGAGCATCATGAAGGTCGTGCTGGGGC TGGCTCTTCAGTTCCTCTGCAGCTATATCACCTTCCCGCTCTACGCGCTC GTCACACAGATGGGATCAAACATGAAGAGGTCCATCTTCGACGAGCAGAC GGCCAAGGCGCTGACAAACTGGCGGAACACGGCCAAGGAGAAGAAGAAGG TCCGAGACACGGACATGCTGATGGCGCAGATGATCGGCGACGCGACGCCC AGCCGAGGGGCGTCGCCCATGCCTAGCCGGGGCTCGTCGCCAGTGCACCT GCTTCACAAGGGCATGGGACGGTCCGACGATCCCCAGAGCACGCCAACCT CGCCAAGGGCCATGGAGGAGGCTAGGGACATGTACCCGGTTGTGGTGGCG CATCCAGTGCACAGACTAAATCCTGCTGACAGGAGAAGGTCGGTCTCTTC GTCGGCACTCGATGCCGACATCCCCAGCGCAGATTTTTCCTTCAGCCAGG GATGA

[0215] SEQ ID NO. 4 The amino acid sequence of wild type TAMLO-A1:534aa

TABLE-US-00013 MAEDDGYPPARTLPETPSWAVALVFAVMIIVSVLLEHALHKLGQWFHKRH KNALAEALEKMKAELMLVGFISLLLAVTQDPISGICISQKAASIMRPCKV EPGSVKSKYKDYYCAKEGKVALMSTGSLHQLHIFIFVLAVFHVTYSVIIM ALSRLKMRTWKKWETETASLEYQFANDPARFRFTHQTSFVKRHLGLSSTP GVRWVVAFFRQFFRSVTKVDYLTLRAGFINAHLSQNSKFDFHKYIKRSME DDFKVVVGISLPLWAVAILTLFLDIDGIGTLTWVSFIPLIILLCVGTKLE MIIMEMALEIQDRSSVIKGAPVVEPSNKFFWFHRPDWVLFFIHLTLFQNA FQMAHFVWTVATPGLKDCFHMNIGLSIMKVVLGLALQFLCSYITFPLYAL VTQMGSNMKRSIFDEQTAKALTNWRNTAKEKKKVRDTDMLMAQMIGDATP SRGTSPMPSRGSSPVHLLQKGMGRSDDPQSAPTSPRTMEEARDMYPVVVA HPVHRLNPADRRRSVSSSALDADIPSADFSFSQG

[0216] SEQ ID NO. 5 The amino acid sequence of wild type TaMLO-B1: 534aa.

TABLE-US-00014 MAEDDGYPPARTLPETPSWAVALVFAVMIIVSVLLEHALHKLGQWFHKRH KNALAEALEKIKAELMLVGFISLLLAVTQDPISGICISEKAASIMRPCKL PPGSVKSKYKDYYCAKQGKVSLMSTGSLHQLHIFIFVLAVFHVTYSVIIM ALSRLKMRTWKKWETETASLEYQFANDPARFRFTHQTSFVKRHLGLSSTP GVRWVVAFFRQFFRSVTKVDYLTLRAGFINAHLSHNSKFDFHKYIKRSME DDFKVVVGISLPLWCVAILTLFLDIDGIGTLTWISFIPLVILLCVGTKLE MIIMEMALEIQDRASVIKGAPVVEPSNKFFWFHRPDWVLFFIHLTLFQNA FQMAHFVWTVATPGLKKCFHMHIGLSIMKVVLGLALQFLCSYITFPLYAL VTQMGSNMKRSIFDEQTAKALTNWRNTAKEKKKVRDTDMLMAQMIGDATP SRGASPMPSRGSSPVHLLHKGMGRSDDPQSTPTSPRAMEEARDMYPVVVA HPVHRLNPADRRRSVSSSALDVDIPSADFSFSQG

[0217] SEQ ID NO. 6 The amino acid sequence of wild type TaMLO-D1: 534aa

TABLE-US-00015 MAEDDGYPPARTLPETPSWAVALVFAVMIIVSVLLEHALHKLGQWFHKRH KNALAEALEKIKAELMLVGFISLLLAVTQDPISGICISEKAASIMRPCSL PPGSVKSKYKDYYCAKKGKVSLMSTGSLHQLHIFIFVLAVFHVTYSVIIM ALSRLKMRTWKKWETETASLEYQFANDPARFRFTHQTSFVKRHLGLSSTP GIRWVVAFFRQFFRSVTKVDYLTLRAGFINAHLSHNSKFDFHKYIKRSME DDFKVVVG1SLPLWCVAILTLFLDIDGIGTLTWISFIPLVILLCVGTKLE MIIMEMALEIQDRASVIKGAPVVEPSNKFFWFHRPDWVLFFIHLTLFQNA FQMAHFVWTVATPGLKKCFHMHIGLSIMKVVLGLALQFLCSYITFPLYAL VTQMGSNMKRSIFDEQTAKALTNWRNTAKEKKKVRDTDMLMAQMIGDATP SRGASPMPSRGSSPVHLLHKGMGRSDDPQSTPTSPRAMEEARDMYPVVVA HPVHRLNPADRRRSVSSSALDADIPSADFSFSQG

[0218] SEQ ID NO. 11 The coding sequence of TALENs (TAL-L+TAL-R) in vector pYP010.

TABLE-US-00016 ATGGTGGATCTACGCACGCTCGGCTACAGTCAGCAGCAGCAAGAGAAGAT CAAACCGAAGGTGCGTTCGACAGTGGCGCAGCACCACGAGGCACTGGTGG GCCATGGGTTTACACACGCGCACATCGTTGCGCTCAGCCAACACCCGGCA GCGTTAGGGACCGTCGCTGTCACGTATCAGCACATAATCACGGCGTTGCC AGAGGCGACACACGAAGACATCGTTGGCGTCGGCAAACAGTGGTCCGGCG CACGCGCCCTGGAGGCCTTGCTCACGGATGCGGGGGAGTTGAGAGGTCCG CCGTTACAGTTGGACACAGGCCAACTTGTGAAGATTGCAAAACGTGGCGG CGTGACCGCAATGGAGGCAGTGCATGCATCGCGCAATGCACTGACGGGTG CCCCCCTGAACCTGACCCCGGACCAAGTGGTGGCTATCGCCAGCCACGAT GGCGGCAAGCAAGCGCTCGAAACGGTGCAGCGGCTGTTGCCGGTGCTGTG CCAGGACCATGGCCTGACCCCGGACCAAGTGGTGGCTATCGCCAGCAACA ATGGCGGCAAGCAAGCGCTCGAAACGGTGCAGCGGCTGTTGCCGGTGCTG TGCCAGGACCATGGCCTGACTCCGGACCAAGTGGTGGCTATCGCCAGCCA CGATGGCGGCAAGCAAGCGCTCGAAACGGTGCAGCGGCTGTTGCCGGTGC TGTGCCAGGACCATGGCCTGACCCCGGACCAAGTGGTGGCTATCGCCAGC AACGGTGGCGGCAAGCAAGCGCTCGAAACGGTGCAGCGGCTGTTGCCGGT GCTGTGCCAGGACCATGGCCTGACCCCGGACCAAGTGGTGGCTATCGCCA GCAACAATGGCGGCAAGCAAGCGCTCGAAACGGTGCAGCGGCTGTTGCCG GTGCTGTGCCAGGACCATGGCCTGACTCCGGACCAAGTGGTGGCTATCGC CAGCCACGATGGCGGCAAGCAAGCGCTCGAAACGGTGCAGCGGCTGTTGC CGGTGCTGTGCCAGGACCATGGCCTGACCCCGGACCAAGTGGTGGCTATC GCCAGCAACGGTGGCGGCAAGCAAGCGCTCGAAACGGTGCAGCGGCTGTT GCCGGTGCTGTGCCAGGACCATGGCCTGACCCCGGACCAAGTGGTGGCTA TCGCCAGCAACAATGGCGGCAAGCAAGCGCTCGAAACGGTGCAGCGGCTG TTGCCGGTGCTGTGCCAGGACCATGGCCTGACTCCGGACCAAGTGGTGGC TATCGCCAGCCACGATGGCGGCAAGCAAGCGCTCGAAACGGTGCAGCGGC TGTTGCCGGTGCTGTGCCAGGACCATGGCCTGACCCCGGACCAAGTGGTG GCTATCGCCAGCAACGGTGGCGGCAAGCAAGCGCTCGAAACGGTGCAGCG GCTGTTGCCGGTGCTGTGCCAGGACCATGGCCTGACCCCGGACCAAGTGG TGGCTATCGCCAGCCACGATGGCGGCAAGCAAGCGCTCGAAACGGTGCAG CGGCTGTTGCCGGTGCTGTGCCAGGACCATGGCCTGACCCCGGACCAAGT GGTGGCTATCGCCAGCAACAATGGCGGCAAGCAAGCGCTCGAAACGGTGC AGCGGCTGTTGCCGGTGCTGTGCCAGGACCATGGCCTGACTCCGGACCAA GTGGTGGCTATCGCCAGCCACGATGGCGGCAAGCAAGCGCTCGAAACGGT GCAGCGGCTGTTGCCGGTGCTGTGCCAGGACCATGGCCTGACTCCGGACC AAGTGGTGGCTATCGCCAGCCACGATGGCGGCAAGCAAGCGCTCGAAACG GTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGACCATGGCCTGACCCCGGA CCAAGTGGTGGCTATCGCCAGCAACAATGGCGGCAAGCAAGCGCTCGAAA CGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGACCATGGCCTGACCCCG GACCAAGTGGTGGCTATCGCCAGCAACGGTGGCGGCAAGCAAGCGCTCGA AAGCATTGTGGCCCAGCTGAGCCGGCCTGATCCGGCGTTGGCCGCGTTGA CCAACGACCACCTCGTCGCCTTGGCCTGCCTCGGCGGACGTCCTGCCATG GATGCAGTGAAAAAGGGATTGCCGCACGCGCCGGAATTGATCAGAAGAGT CAATCGCCGTATTGGCGAACGCACGTCCCATCGCGTTGCCGGATCCCAGC TGGTGAAGTCCGAGCTGGAAGAAAAAAAGAGCGAGCTGCGCCACAAGCTC AAGTACGTGCCCCACGAGTACATCGAGCTGATCGAGATCGCCCGCAACAG CACCCAAGACCGCATCCTGGAGATGAAAGTGATGGAGTTCTTCATGAAGG TGTACGGCTACCGCGGCAAGCACCTGGGCGGCTCCCGCAAGCCCGATGGC GCCATCTACACCGTGGGCTCCCCCATCGACTATGGCGTCATTGTCGACAC CAAGGCCTACTCCGGCGGCTACAACTTACCCATCGGTCAGGCCGACGAGA TGCAACGCTACGTGAAGGAGAACCAGACCCGCAATAAGCACATTAATCCC AACGAGTGGTGGAAGGTGTACCCCTCCTCCGTGACCGAGTTCAAATTCCT GTTCGTGTCCGGCCACTTCAAGGGCAATTATAAGGCCCAACTGACCCGCC TGAACCACAAGACCAACTGCAACGGCGCCGTGCTGTCCGTGGAGGAACTG CTGATCGGCGGCGAGATGATCAAGGCTGGTACCCTGACCCTGGAAGAGGT GCGCCGCAAGTTCAACAATGGTGAAATCAATTTCAGGTCCGGCGGCGGAG AGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGAGGAGAATCCCGGC CCTAGGATGGACTACAAAGACCATGACGGTGATTATAAAGATCATGACAT CGATTACAAGGATGACGATGACAAGATGGCCCCCAAGAAGAAGAGGAAGG TGGGCATTCACGGGGTGCCGGCTAGCATGGTGGATCTACGCACGCTCGGC TACAGTCAGCAGCAGCAAGAGAAGATCAAACCGAAGGTGCGTTCGACAGT GGCGCAGCACCACGAGGCACTGGTGGGCCATGGGTTTACACACGCGCACA TCGTTGCGCTCAGCCAACACCCGGCAGCGTTAGGGACCGTCGCTGTCACG TATCAGCACATAATCACGGCGTTGCCAGAGGCGACACACGAAGACATCGT TGGCGTCGGCAAACAGTGGTCCGGCGCACGCGCCCTGGAGGCCTTGCTCA CGGATGCGGGGGAGTTGAGAGGTCCGCCGTTACAGTTGGACACAGGCCAA CTTGTGAAGATTGCAAAACGTGGCGGCGTGACCGCAATGGAGGCAGTGCA TGCATCGCGCAATGCACTGACGGGTGCCCCCCTGAACCTGACCCCGGACC AAGTGGTGGCTATCGCCAGCAACAAGGGCGGCAAGCAAGCGCTCGAAACG GTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGACCATGGCCTGACCCCGGA CCAAGTGGTGGCTATCGCCAGCAACAAGGGCGGCAAGCAAGCGCTCGAAA CGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGACCATGGCCTGACCCCG GACCAAGTGGTGGCTATCGCCAGCAACAAGGGCGGCAAGCAAGCGCTCGA AACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGACCATGGCCTGACCC CGGACCAAGTGGTGGCTATCGCCAGCAACATTGGCGGCAAGCAAGCGCTC GAAACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGACCATGGCCTGAC CCCGGACCAAGTGGTGGCTATCGCCAGCAACAAGGGCGGCAAGCAAGCGC TCGAAACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGACCATGGCCTG ACCCCGGACCAAGTGGTGGCTATCGCCAGCAACATTGGCGGCAAGCAAGC GCTCGAAACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGACCATGGCC TGACCCCGGACCAAGTGGTGGCTATCGCCAGCAACGGTGGCGGCAAGCAA GCGCTCGAAACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGACCATGG CCTGACCCCGGACCAAGTGGTGGCTATCGCCAGCAACAAGGGCGGCAAGC AAGCGCTCGAAACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGACCAT GGCCTGACTCCGGACCAAGTGGTGGCTATCGCCAGCCACGATGGCGGCAA GCAAGCGCTCGAAACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGACC ATGGCCTGACCCCGGACCAAGTGGTGGCTATCGCCAGCAACATTGGCGGC AAGCAAGCGCTCGAAACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGA CCATGGCCTGACCCCGGACCAAGTGGTGGCTATCGCCAGCAACGGTGGCG GCAAGCAAGCGCTCGAAACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAG GACCATGGCCTGACCCCGGACCAAGTGGTGGCTATCGCCAGCAACATTGG CGGCAAGCAAGCGCTCGAAACGGTGCAGCGGCTGTTGCCGGTGCTGTGCC AGGACCATGGCCTGACCCCGGACCAAGTGGTGGCTATCGCCAGCAACGGT GGCGGCAAGCAAGCGCTCGAAACGGTGCAGCGGCTGTTGCCGGTGCTGTG CCAGGACCATGGCCTGACTCCGGACCAAGTGGTGGCTATCGCCAGCCACG ATGGCGGCAAGCAAGCGCTCGAAACGGTGCAGCGGCTGTTGCCGGTGCTG TGCCAGGACCATGGCCTGACTCCGGACCAAGTGGTGGCTATCGCCAGCCA CGATGGCGGCAAGCAAGCGCTCGAAACGGTGCAGCGGCTGTTGCCGGTGC TGTGCCAGGACCATGGCCTGACTCCGGACCAAGTGGTGGCTATCGCCAGC CACGATGGCGGCAAGCAAGCGCTCGAAACGGTGCAGCGGCTGTTGCCGGT GCTGTGCCAGGACCATGGCCTGACCCCGGACCAAGTGGTGGCTATCGCCA GCAACAAGGGCGGCAAGCAAGCGCTCGAAAGCATTGTGGCCCAGCTGAGC CGGCCTGATCCGGCGTTGGCCGCGTTGACCAACGACCACCTCGTCGCCTT GGCCTGCCTCGGCGGACGTCCTGCCATGGATGCAGTGAAAAAGGGATTGC CGCACGCGCCGGAATTGATCAGAAGAGTCAATCGCCGTATTGGCGAACGC ACGTCCCATCGCGTTGCCAGATCTCAACTAGTCAAAAGTGAACTGGAGGA GAAGAAATCTGAACTTCGTCATAAATTGAAATATGTGCCTCATGAATATA TTGAATTAATTGAAATTGCCAGAAATTCCACTCAGGATAGAATTCTTGAA ATGAAGGTAATGGAATTTTTTATGAAAGTTTATGGATATAGAGGTAAACA TTTGGGTGGATCAAGGAAACCGGACGGAGCAATTTATACTGTCGGATCTC CTATTGATTACGGTGTGATCGTGGATACTAAAGCTTATAGCGGAGGTTAT AATCTGCCAATTGGCCAAGCAGATGAAATGGAGCGATATGTCGAAGAAAA TCAAACACGAAACAAACATCTCAACCCTAATGAATGGTGGAAAGTCTATC CATCTTCTGTAACGGAATTTAAGTTTTTATTTGTGAGTGGTCACTTTAAA GGAAACTACAAAGCTCAGCTTACACGATTAAATCATATCACTAATTGTAA TGGAGCTGTTCTTAGTGTAGAAGAGCTTTTAATTGGTGGAGAAATGATTA AAGCCGGCACATTAACCTTAGAGGAAGTGAGACGGAAATTTAATAACGGC GAGATAAACTTTTAATAG

[0219] SEQ ID NO. 12 The amino acid sequence of the TALENs.

TABLE-US-00017 MVDLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQHPA ALGTVAVTYQHIITALPEATHEDIVGVGKQWSGARALEALLTDAGELRGP PLQLDTGQLVKIAKRGGVTAMEAVHASRNALTGAPLNLTPDQVVAIASHD GGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVL CQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIAS NGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLP VLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAI ASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRL LPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVV AIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQ RLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQ VVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALET VQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTP DQVVAIASNGGGKQALESIVAQLSRPDPALAALTNDHLVALACLGGRPAM DAVKKGLPHAPELIRRVNRRIGERTSHRVAGSQLVKSELEEKKSELRHKL KYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGKHLGGSRKPDG AIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVKENQTRNKHINP NEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHKTNCNGAVLSVEEL LIGGEMIKAGTLTLEEVRRKFNNGEINFRSGGGEGRGSLLTCGDVEENPG PRMDYKDHDGDYKDHDIDYKDDDDKMAPKKKRKVGIHGVPASMVDLRTLG YSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQHPAALGTVAVT YQHIITALPEATHEDIVGVGKQWSGARALEALLTDAGELRGPPLQLDTGQ LVKIAKRGGVTAMEAVHASRNALTGAPLNLTPDQVVAIASNKGGKQALET VQRLLPVLCQDHGLTPDQVVAIASNKGGKQALETVQRLLPVLCQDHGLTP DQVVAIASNKGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQAL ETVQRLLPVLCQDHGLTPDQVVAIASNKGGKQALETVQRLLPVLCQDHGL TPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQ ALETVQRLLPVLCQDHGLTPDQVVAIASNKGGKQALETVQRLLPVLCQDH GLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGG KQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQ DHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNG GGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVL CQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIAS HDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNKGGKQALESIVAQLS RPDPALAALTNDHLVALACLGGRPAMDAVKKGLPHAPELIRRVNRRIGER TSHRVARSQLVKSELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILE MKVMEFFMKVYGYRGKHLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGY NLPIGQADEMERYVEENQTRNKHLNPNEWWKVYPSSVTEFKFLFVSGHFK GNYKAQLTRLNHITNCNGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNG EINF

[0220] Nucleic acid sequence of Tamlo-A in line Tamlo-R32 (coding sequence) SEQ ID NO. 38

TABLE-US-00018 1 ATGGCGGAGGACGACGGGTACCCCCCGGCGCGGACGCTGCCGGAGACGCCGTCCTGGGCG 61 GTGGCGCTGGTCTTCGCCGTCATGATCATCGTCTCCGTCCTCCTGGAGCACGCGCTCCAC 121 AAGCTCGGCCATGTAAGTCCCCTCACTCCCGCAACAAGAACAAGAACAAGAACAAGAACA 181 ACCAGAACCAGAATCAGCTCATGGCTTCCTTTCCTCCCTTGGTGCGTGTAAGCAGTGGTT 241 CCACAAGCGGCACAAGAACGCGCTGGCGGAGGCGCTGGAGAAGATGAAGGCGGAGCTGAT 301 GCTGGTGGGATTCATCTCGCTGCTGCTCGCCGTCACGCGAAGGTGACCGCGGTGATGATG 361 ATGATGATGGAACTTGTTCTCGCCCGTGGTGACCCAATCTCCGGGATATGCATCTCCCAG 421 AAGGCCGCCAGCATCATGCGCCCCTGCAAGGTGGAACCCGGTTCCGTCAAGAGCAAGTAC 481 AAGGACTACTACTGCGCCAAAGAGGTAACTAACACAAACAGTTTCTTCTTCTTCTTGTTG 541 TTTTCCTTCCTGATTGGCTTGGCCTGATTGGTGTGGTGTCTGTTTCTCCTGCAGGGCAAG 601 GTGGCGCTCATGTCCACGGGCAGCCTGCACCAGCTCCACATATTCATCTTCGTGCTAGCC 661 GTCTTCCATGTCACCTACAGCGTCATCATCATGGCTCTAAGCCGTCTCAAGGTGAGCCTT 721 TCTTTCTTTCTTTCCCGTGCTTCCAGATCCTGCGCGGTTCCCGGGCAAGGTGGCGCTCAT 781 CGTACGTCTGTCTCAGTTAAACTGCTACCAATCCTTAACCTGCTCCGGCATAATATTCTT 841 ATTCCTCCCCCCGGCAGATGAGAACATGGAAGAAATGGGAGACAGAGACCGCCTCCTTGG 901 AATACCAGTTCGCAAATGGTCAGACAATTTTCCAAATGAAACCTCTTCTGTTTTGATGCG 961 TTTACAGAGGCAGGCATGATCAGAGCGAGTGAACTGATGATATGTTCTTCTCTTTCCCGT 1021 GCTTCCAGATCCTGCGCGGTTCCGCTTCACGCACCAGACGTCGTTCGTGAAGCGGCACCT 1081 GGGCCTGTCCAGCACCCCCGGCGTCAGATGGGTGGTGGCCTTCTTCAGGCAGTTCTTCAG 1141 GTCGGTCACCAAGGTGGACTACCTCACCTTGAGGGCAGGCTTCATCAACGTACGTAATAC 1201 CCCAAAAGCCCCCTCTCCTTCTAGCTCCGTCGGCCATTGCCGCGACGCTTCTGAAATAAG 1261 TACTGTTCCAACACCAATGATCACATGCTCTCTCTTTCCATGATTCTGCGCAGGCGCACT 1321 TGTCGCAGAACAGCAAGTTCGACTTCCACAAGTACATCAAGAGGTCCATGGAGGACGACT 1381 TCAAAGTCGTCGTTGGCATCAGGTAGGTTGCATTCCATGGATATGATTATACAATTGTCG 1441 TCAGGCTCCATATGATATTGCTTAGCTTCCATATGATACAATACTATCAGTTTGCTGCGT 1501 CATGGTCTTTGCCCCTGCTGGTCCTTGTTGCATGATCTTGACACATTTGGCCTCTTTTCG 1561 CAGCCTCCCGCTGTGGGCTGTGGCGATCCTCACCCTCTTCCTTGATATCGACGGTATGGA 1621 CCTTGTCTTTGCCCCCTTCTCTGTTGCCTTGCTGCTAAAACACTTGTAATTTATTTGTCT 1681 CGTAACCACCGTTCATTTTCTAACCTTTCCCCCCTTTCTTTCTGCTCATAGGGATCGGCA 1741 CACTCACCTGGGTTTCTTTCATCCCTCTCATCGTAAGTGCGAATTTCTCCGCCGAAAGCA 1801 ACAGCCAAACCCCATTTGATTGCAATGCGAAATCACACCTAATAATAATTCAAATTGTCA 1861 TTGTCCATCTGTCTTTCCCAGATCCTCTTGTGTGTTGGAACCAAGCTAGAGATGATCATC 1921 ATGGAGATGGCCCTGGAGATCCAGGACCGGTCGAGCGTCATCAAGGGGGCACCCGTGGTC 1981 GAGCCCAGCAACAAGTTCTTCTGGTTCCACCGCCCCGACTGGGTCCTCTTCTTCATACAC 2041 CTGACGCTGTTCCAGAACGCGTTTCAGATGGCACATTTCGTGTGGACAGTGGTACGCCGC 2101 GGATGAACTTGTCAGTTAATAATATGGGTGTCAAGGCACCAAGTGCTGCTGCTGATGAAC 2161 TGCACTGACAGAGATTTACCTGTGTCGCAGGCCACGCCCGGCTTGAAGGACTGCTTCCAT 2221 ATGAACATCGGGCTGAGCATCATGAAGGTCGTGCTGGGGCTGGCTCTCCAGTTCCTGTGC 2281 AGCTACATCACCTTCCCCCTCTACGCGCTAGTCACACAGGTAATAAAACCGTTGATGAAG 2341 ATCTCTGAACAATTGCTCTGGGAGAGGAGAAACAGCAGCCTTAATCATCTGTGTGCGCTG 2401 GCTTTGTACGCAGATGGGATCAAACATGAAGAGGTCCATCTTCGACGAGCAGACAGCCAA 2461 GGCGCTGACCAACTGGCGGAACACGGCCAAGGAGAAGAAGAAGGTCCGAGACACGGACAT 2521 GCTGATGGCGCAGATGATCGGCGACGCAACACCCAGCCGAGGCACGTCCCCGATGCCTAG 2581 CCGGGGCTCATCGCCGGTGCACCTGCTTCAGAAGGGCATGGGACGGTCTGACGATCCCCA 2641 GAGCGCACCGACCTCGCCAAGGACCATGGAGGAGGCTAGGGACATGTACCCGGTTGTGGT 2701 GGCGCATCCTGTACACAGACTAAATCCTGCTGACAGGAGAAGGTCGGTCTCTTCATCAGC 2761 CCTCGATGCCGACATCCCCAGCGCAGATTTTTCCTTCAGCCAGGGATGA

[0221] Nucleic acid sequence of Tamlo-D1 in line Tamlo-R32 (coding sequence) SEQ ID NO. 39

TABLE-US-00019 1 ATGGCGGAGGACGACGGGTACCCCCCGGCGCGGACGCTGCCGGAGACGCCGTCCTGGGCG 61 GTGGCGCTCGTCTTCGCCGTCATGATCATCGTGTCCGTCCTCCTGGAGCACGCGCTCCAC 121 AAGCTCGGCCATGTAAGTTCCCTCACTCCTGCAACAAGAAAAAAAAAAGCCTCAACCAGA 181 ATCAGCAGCTCAGCTCATGGCTTCCTCTGCTCCCTTGGTGCACCTGCAGTGGTTCCACAA 241 GCGGCACAAGAACGCGCTGGCGGAGGCGCTGGAGAAGATCAAAGCGGAGCTGATGCTGGT 301 GGGGTTCATCTCGCTGCTGCTCCATCTCCGAGAAGGCCGCCAGCATCATGCGGCCCTGCA 361 GCCTGCCCCCTGGTTCCGTCAAGAGCAAGTACAAAGACTACTACTGCGCCAAAAAGGTGA 421 GCCTGCTACAAGCTACTCCCGGAGACGGCCGGGAAAAACACAAACAGATTCCGGCGGCCG 481 GCCGGAGTTTCTTCTTGTTTCCTTCCTGATTGGCTTGGCCTAATTGGTGTGTGTTTTTCT 541 GGCAGGGCAAGGTGTCGCTAATGTCCACGGGCAGCTTGCACCAGCTCCACATATTCATCT 601 TCGTGCTCGCCGTCTTCCATGTCACCTACAGCGTCATCATCATGGCTCTAAGCCGTCTCA 661 AAGTGAGTCTGTCAGGCCTACCTGTTCATGCTTCGGTAAAGCAATAAAACTACTTGCTAC 721 CAATCCCTAATCTGCTCCCTCAGGCATAATATTGTTCCTTCTTTCCTGCTGCAGATGAGG 781 ACATGGAAGAAATGGGAGACAGAGACCGCCTCCTTGGAATACCAGTTCGCAAATGGTCAG 841 ACAATTTCCGAAATGAAACCTGACTGATGCATTTACAAACGCACGCAGGCAGGCATGATC 901 AGAGTGAGTGAACTGATGATATGTTTTCTCTCTCTTTCCCGTGCCTCCAGATCCTGCGCG 961 GTTCCGCTTCACGCACCAGACGTCGTTCGTGAAGCGTCACCTGGGCCTCTCCAGCACCCC 1021 CGGCATCAGATGGGTGGTGGCCTTCTTCAGGCAGTTCTTCAGGTCGGTCACCAAGGTGGA 1081 CTACCTCACCCTGAGGGCAGGCTTCATCAACGTACGTACCAAAACAAATCCTCTCCCTCT 1141 AGCTTCGCCATTGCTGCGACGCTTCTGAAATATGTACCGTTCCGACACCAGCGATCTCAT 1201 GTCTTCTCTTTCCACGATTCTGCGCAGGCGCATTTGTCGCATAACAGCAAGTTCGACTTC 1261 CACAAGTACATCAAGAGGTCCATGGAGGACGACTTCAAAGTCGTCGTTGGCATCAGGTAG 1321 GTTACATTCCATGGATAGGATTATAAAATTGCCGTCAGGCTCCATATGATATTGCTTAGG 1381 TTCCACATGATACAATACTATCAGTTTGCTGCGTCATGGTCTTTGCCCCTGCTGGTCTTC 1441 CTTGCGTGATCTTGACACATTTGGCCTCTTTTCGCAGCCTCCCGCTGTGGTGTGTGGCGA 1501 TCCTCACCCTCTTCCTTGATATTGACGGTATGGACCTTGCTAAAACACTTGTAATTTGTC 1561 TCGTAACCACCGTTCATTTTCTAACCTTCCTTTCCCCTTCTTTCTGCTGGCAGGGATCGG 1621 CACGCTCACCTGGATTTCTTTCATCCCTCTCGTCGTAAGTGCGAATTTCTCCGCCGAAAG 1681 CAACAGCCAGCCCCATTTGATTGCAATGCGAAACCACACCTTAATTGAAAATGTCATTGT 1741 CTGTCTTGTCTTTCTCAGATCCTCTTGTGTGTTGGAACCAAGCTGGAGATGATCATCATG 1801 GAGATGGCCCTGGAGATCCAGGACCGGGCGAGCGTCATCAAGGGGGCGCCCGTGGTTGAG 1861 CCCAGCAACAAGTTCTTCTGGTTCCACCGCCCCGACTGGGTCCTCTTCTTCATACACCTG 1921 ACGCTGTTCCAGAATGCGTTTCAGATGGCACATTTCGTCTGGACAGTGGTATGTACCAGT 1981 AATTGGCAGTTCAGTTAGGGATGCAAGGCACCAAGTAGTGCTGATGAACTGCACTGACGG 2041 AGATTTACTTGTTCGTAGGCCACGCCCGGCTTGAAGAAATGCTTCCATATGCACATCGGG 2101 CTGAGCATCATGAAGGTCGTGCTGGGGCTGGCTCTTCAGTTCCTCTGCAGCTATATCACC 2161 TTCCCGCTCTACGCGCTCGTCACACAGGTAATAAAGCCGTTGATGAAGATGTCTGAACAA 2221 TTGCTCTGGGAGAGGAGAAACAGCAGCCTTAATCATGTAATCGGTGTGATGGGTTGCAGA 2281 TGGGATCAAACATGAAGAGGTCCATCTTCGACGAGCAGACGGCCAAGGCGCTGACAAACT 2341 GGCGGAACACGGCCAAGGAGAAGAAGAAGGTCCGAGACACGGACATGCTGATGGCGCAGA 2401 TGATCGGCGACGCGACGCCCAGCCGAGGGGCGTCGCCCATGCCTAGCCGGGGCTCGTCGC 2461 CAGTGCACCTGCTTCACAAGGGCATGGGACGGTCCGACGATCCCCAGAGCACGCCAACCT 2521 CGCCAAGGGCCATGGAGGAGGCTAGGGACATGTACCCGGTTGTGGTGGCGCATCCAGTGC 2581 ACAGACTAAATCCTGCTGACAGGAGAAGGTCGGTCTCTTCGTCGGCACTCGATGCCGACA 2641 TCCCCAGCGCAGATTTTTCCTTCAGCCAGGGATGA

[0222] Tamlo-R32-A upstream sequence (3000 bp); ATG start codon in bold and underlined SEQ ID NO. 40

TABLE-US-00020 1 GTGCGCCACTGCTATATAGCAGTGGCGCACCACCATCATGGTGCGCCACTAATAGGGATA 61 TTGGCTATAGCCATTTTTCTAGTAGTGTAAGCACAAGAAATAAAAAAAATATGGAAAACC 121 CTCACATCTCATCTTAAATTCTCAGAGTTAGTAATACGAAATTCAACGCAAATCAGGGAG 181 TAGGACAACGAGACGAAAGTGATTCCCCCGTAGCTCTTTTATTTCGCGAGGGCTCTGATC 241 ATGTATAGCTAGCCATGCATAGACAACATGACAGGCATGTTTTGGGTGCCCACAGCACAC 301 ACAAGTTGTGAAACAGTACGTGCATGACTGGGCACAGAGCAGGTTAGAGCAAACCTCCAC 361 ATCACCATAAATTCCGAGTAGCCACTAGATTCAGCATGCCTGTTTAGGGTTCTGTACAGT 421 ACGTACCTGGCTACTACTGCTTGCCAATTGAAAAATGATTTAGAGCAAATTCCAGAATGC 481 CATGACACATCTGCTTTTATGTCAAACCCACTGTTCATAACAATATTTGTGCGGTGGTGT 541 GCATGAGATAAGATCCGGATGAGGGTGGCGCCCATAAAAAATGGGCCATTCATGAACCAG 601 CAGCGTCAACACGAACGAGCGACGAAGCCGCGGGCTACGAGCGTCACCACACAATATGTT 661 AATGGATCGGGCCGGCCATCCCATCGGCCATCAGGGTGTGCTGCCAAGCAGATCTCCATG 721 CATGATGCATCACGGGTGCACCTAGTAGCCACATAGATCTCCAGACTCCAGGCATGATGC 781 ATCACGGGTGCATCTGTATATTCAAACCTACCATTAACTTTGCCCGATCAGAGGAACCGG 841 TCCGGATCCGATCGTTAATTCGGCGACCAGTGACTTGATCGCGTCTGTTTAAGCACTAGC 901 AGCTCACTGATCGCATGGATCGACCGCTGGTAAGAATAGTACACCCTGTGCATATACAAG 961 TCCGCGAAAAAGTAGCAGCCACGAATGCAGTCAACGTTTTTATTTGACCTGACTCGCTCG 1021 ATCAGGCCCGTACTCCACTGGTTGAAACGCCCACTTCGCCGGAGCCGCCTGGTCAGACTT 1081 TTCCACGCACGACCGACCATTGAGCAGTCAAAGTTCGGATGCCACGCCGTCGCTCGCATG 1141 CGGACGTACGTGTGCAAGTCGTCGCAACTTGCGTGCTACAGAAATTCAAAACAAAACAAA 1201 AAAACTTGCGTGGCACAGTACGAGACTACAAGCGAGTAGAAGCGCACCACGTATGCCCGT 1261 GTATCTGCAGTAACGGAACCGTGCACGTTTTGGCTAAACGTGCGCATGCAGCAGGGTGCA 1321 CGTCCACGTCCTGCAGGTTTAAGTATATAATGTAGCTTACAGTAATTAACCATGCATGCT 1381 TCGAAATGAAGCACTGCCTGCCGGGCGCCGGCGACCTGATCCACCACCACCCGACGCGCG 1441 GCTCGCCGGCGGGAACAGCCAGTCGCGCGCGTGGACCTCTCGCCTCTACCAACGTGTGGC 1501 TACGTGTAACCGTGCTCCGTAAAACCGTGTTGGTTTTACCTTTACCTTTCTCTCGCCCGC 1561 ACACACGTCGCCGCCAAGACATGCGTCGCGTCATTTTCTCCAAATAACTTTGGCGCGAAC 1621 GGGTCTCCGATCGAGCAGCACCAAATCAATCAACCCAACGAAAGTGATCCGACGTCACAA 1681 AATTCGATCCCCCGAGAAACTGGCAGCACTTTTGCCGTTTTCTTGCCGGTCCCAACGAAC 1741 TCTCCGTCCCTCCTAATTTAATGTCAAAAAAATATAAAAAAATCTCCGCCTGCGTTGATG 1801 ATCCCAATAACCAGCAAGCTGTCCTACGGGATCATTCAGGAGCTTTTAGAGCTGCTACTT 1861 GTCATCTCTTTGATGGAATCGCCGATTCGGAGGTTGCTGAAATTTATGCCTGCAAACGAG 1921 CTTTATAGGTGGCGGCCGAACTCAACACATCCAAGCTGTTGTTGGAGACGGACTGTGCTA 1981 ATCTAGCAAAGATGTTGTGTGCGCAAGAGAAAACTCTCTCTGCATTTGGACCTCTGGTGA 2041 AGGAGATCAAGGAGAGGATGAAAATGTTCCAAGAAGTGAAAATGTCTTGCGTAAGGCGTA 2101 GTGCTAATGCTGCCGCGGATAAGTTAGCTAAAGTTGGGTTAAGTGATAGACTGTGTAAGG 2161 TTTGGTTTGCCGTTCCCCCAGATTGTATTCTGGGCATTGTGTCGGACGAGATTCCTAATT 2221 TCATTTAATTAGTCAATAAAGCGGCAGTAGTTGATCCTCAAAAAAAATAACCAGCAAGCT 2281 AGCCGGACGCGTCGGTTTTTGTCCTGCCTAAGCTAGGAGTATCTCCAAGTAACCTACGCG 2341 GGACAAAACTATGGCCAGATAGACACTAGTCAAACGATCGCAACAAGAAAAAAACTAGTC 2401 AAGAAAAATACTACAGATTACCTAAAGAAAAAAAATAGAAAACCAAAACAAAAATACTGG 2461 TAAAGTGACCGTCCCCGTCAAAAAATACTTGCCGACCGACCGGGTGTCCCCCGTCGCCCC 2521 GGCCCGGTGCCGGCCGAGCACCCCGCCCAGAGCGCCATCACTGGATCAACCACCCCGTCC 2581 AACCGCGCGCTACGAAACATCGGTCGTTTCTCACGGTGCAATCTCAGCCGGAAACCGGCG 2641 CTCGCGCGCATCAGCTGTAGCCTGTAGGTCTCGGGCTCCGCAGCGCCGCTGCCGAGCCAC 2701 CCGGCCGGCGCGCACGCACGCACGCGCTTTGACCCGGCCGCCGATAAAAGGCCCCGCGCG 2761 GCAGCTCCCTCCTACCCGGTTGCCACACCCACAGTCTGCCACAGCAGCAACAAGCTAGAC 2821 ATACCTGCGTGCGTACGTACGTTTTCGTTTTCCTTTCTTGCTCCGGCCGGCCGGCCGGCC 2881 ACGTAGAATAGATACCTGCCCAGGTACGTACCTCGTTGGCTCAGACGATCGGCGGTTGGA 2941 CTTGGGTGCGCGCCCTGCCCTGCTCCGGCCAAGGAAAGAGGTTGCGCTAAAGACGGGCGG 3001 ATG

[0223] Tamlo-R32-B upstream sequence (3500 bp); ATG start codon in bold and underlined SEQ ID NO. 41

TABLE-US-00021 1 CCCCGTAGCTCTTTTATTTCGCGAGGGCTTTGATCATGTATAGCTAGCCATAAACAACAT 61 GACAGGCATGTTTTGGGTGCCCACAGCACACACAAGTTGTGAAACAGTACGTACATGACT 121 GGGCACAGAGCAGGTTAGAGGAAACCTCCACATCATCATAAATTCTGAGGAGCCACTAGA 181 TTCAGCATGTCTGTTTAGGGTTCTGGCTACTTGCCAATAAAAAAATATTATGATTTACTA 241 GCATAGATTCCAGAATGCCATGACATTTCTGCTTTGATTTCAATCCACTGCTCATAACAG 301 AAGCATATGGCCCGGACTCATTAACTTGGTCGTTCCTCATGATTTGTTCTAGTCTCGTTT 361 TATCTCACAAGATGCTTGTTCACAAGGTTGTCAGAATCGCGATTCTGAATCGGATCGGAG 421 CTCCAATGGCAGGATCACAAATCATAGAATCTTCACTATCAGGATCGTGAAAACGTAGAT 481 TCTATGAACCAAAATCATAAAATCAGAGGGGTTAGTTTGAATCGTAAAATCGTAGAATCG 541 TACAACATAATCGCGATTCTGACAACCTTGCTTGTTCATTTGCTGCTATATATATTAGGA 601 CCATGCATATTGGTCACACGAGGGCAGCGCTGCAAGTGCAAAGTCGCCGAGACAAGACTG 661 AGCACCGTTTCATGGGCTTGATCTCTTGGTAAGCAGCCGCCGCCGGACCATCATCAGCCA 721 AGAAAGACACATTCTTGTGCTACTATATTTGTGCGGTTGCGCGCATGAGATAAGATCCGG 781 ATGAGGATGGCGCGCATAAAAAAATGAGCAATGTCAAAGCAGTGTACCCTGAGCTTCCTT 841 CCATTCATGAACCAGTAGCGTCAACTACAGGAACGAGCAACGAACCGTCACCTTATATTA 901 GTGGATCGGGCCCATCCATCCCATCAGGGTGTGCCGTCAAGCAGATCTCCATGCATGCAT 961 CTCGGATTGCACCTAGTAGCCACATAAACAGAGGCTGATTAGTACTACTACAAAGGTACC 1021 GGCTAGGCCAAATCATCTCGCCTCGTTGAAATTCAAACCTGCCATTAACTTTCCCCGATC 1081 AGAAGAAACGGTCCGGATCCGATCGTTAATTCGGCGACCAGTGACTTGATCTCGTCCGTT 1141 TAAGCACTATACTAGCAGCAGATCACTGATCACATGGATGGACCGCTGCTAAGAATAGTA 1201 TATCCTTCCTGCATATACAAGTCCGCAAAAAAGTAGCAGCCACACAAATGCAGTCAACGC 1261 TCCATTTGACTTGACCCGCTCCATCAGGCCCGTACTCCACTGGTTGAAACGCCCACTTCG 1321 CCGGAGCGGCGTGGTCGACTTCTCCACGCAGGGGACCGACCATGAGCAGTCAAACTTGGG 1381 ATGCCACGTCGACCGACGTGTGCAAGTCGTCGCAACTTGCTTGGCACAGTACGAGACCAC 1441 AAGCGAGCAGGAGTGCGCCACGTATACGTGACGGGCCCGTTTGCCTGCAGTGACGGAACC 1501 GTGCACGCTTTGGCTAAATATAAACGTGCGCATGCAGCAGGGCTTACAAGAACCATTAAG 1561 TAACTTTCACGTCCACGTCGTACAGTACATGTTTATATATAACGTCGTAAACTACAGTTA 1621 GCGCATGCTCTAGCGGCATACGGTGCCAGCCGACTGATGGTCCGGCAAGTTTGGGCTGAT 1681 GACCTACCTGATGATGTAAACGTTCAGATGGCCAGCGTTTTGCCTGCGCCCGTGTGATTT 1741 ATGGAATCTGGGTGTTCCATTTAAAAAAAAAAACCCATTCATGCTTCGAAATGAAGCATG 1801 GAGGAAGTCGGACGTCACACAATTCGATCGATCGACCCATCGTTTTTCTCGGCCGGGGAA 1861 GAGGCAAGGCGGGCACAGTTTTGCCCTTTTCGATCGTTTGGTCCGTCCCAACAGATTCTC 1921 CGTCCCCATTAATCAAGTCCAAAACAGGAATACATGCAGCAATACTCTATGCTTGTCCAA 1981 TTAGCAATTACTCTCACGTCAACCGCTGGCGATTAACAATGGCTCTCCGTATGAAAAACT 2041 AACTCGATGGGAGCACCAGGCTAGCCATCGTGCACGCACGTCCCGGCCGGTGAATGTTTC 2101 GACCGTCTGGGTACGAGCCCGACCCGCTCGAAGGTGCCACGCCCCTGCCTACCAGGCGCC 2161 GGCGACCTGATCCACCACCCGACGCGCGGCTCGCCGGCGGGAACAGTCAGTCGCGTTGAC 2221 CTCTCGCCTCTACCAACGTGTGGCTACGTGTAACCGTGGTCCGTAAACCCGTGTTCGTTT 2281 TACCTTACCTTTCTCACGCGCACAATACATGTTTCGCGTCATTTTCTCCACGTAAAACTT 2341 TGGCGCGAACGGGTCTCCGATCGAGCAGCATCAAATCAATCAACCCAACGAAAGTGATCC 2401 GACGTCACACAATTCGATTCCCCAAGAAACGGGGCAGCACATTTGCCGTTTCCTTGCCGG 2461 TCCAACGAACTCTCCGTCCTAATTTAACGTCAGTTTTTTTTCTCCGCCCGCGTTGATGAT 2521 CCCGATAACCAGCAAGCTAGCCAGACGCGTCGGCTTTTGTCCTGCTTAGCTAGGAGTATC 2581 TCCAAGTAACCTTACCTACGCGGGACAAAACTATGGCCAGATATAGATATACTAGTCAAA 2641 CGATGGCAACAAGAACAAAAAAAAACTACTCCCTCCGCTTCTAAATATAAGTTTTTCTAG 2701 AGATTTTACTATAAACTATATACGGACGTATATAGACAAAATTTAAGTGTATATTCACTT 2761 ATTTTGCTCTGTATGTAGTTTTTTGTTGGAATCTCTAAAAAGAAATATAGGAGTATTTAG 2821 GAACAGAGGGAGTAGTCAAGAATAATACTACGGATTCCCTAAAGGAAAAAATAGAAAAAA 2881 AATACTACTAGTATTTTTTGAGAAATAATACTACAAGTAAAGTGACCGTCTCTGTCAGAA 2941 AATACTACGGGACCGACCGGGTGTTCCCCCTCGCCCCGGCCCGGTGCCGGCCGAGCACCC 3001 AGAGTGCCATCACTGGATCAACCACCCCGTCCAACCTCGCGCTAGGAAACATAGCTCGAT 3061 CCCTCAAACAAAAAAAAAAAGGAAACATAGCTCGTATCAGCCGAAACCCGCCACTCGACA 3121 TTCGTATCAGCTCTAGGCAGGTCTCCCGCTCCGCAGCGCGCCGCTGCCGAGCCACCCGGC 3181 CGGCGCGCAGGCGCGCACGCACGCGGTTTGACCCGGCCGCCGCGCGCCCGCGCCGCGCCG 3241 ATAAAAGGCCCCGCGCGGCAGCTCCCTCCCACCCGGTTGCCACGCCCACACTTCGCCAAC 3301 ACACAACGTACCTGCGTACGTACGCTTTCCATTTCCTTTCTTGCTCCGGCCGGCCGGCCA 3361 CGTAGAATAGATACCCGGCCAGGTAGGTACCTCGTTGGCTCAGACGACCGGCGGCTGGGT 3421 CTCCGGACAAGGAAAGAGGTTGCGCTCGGGGACCGATG

[0224] Tamlo-R32-D upstream sequence (3500 bp); ATG start codon in bold and underlined SEQ ID NO. 42

TABLE-US-00022 1 GAGGGAAATGTTTTAGAACTGGGCGAGGGCCCGGACTCATTAACTTGGCTGTTCCTCATG 61 ATCTGTTCTTGTCTCGTTTTATCTCAGGAGATGCTTGTTCATTTGTTGCTATATAATACT 121 TCCTCCGTTCGGAATTACTTGTCGCAGAAATGGATGTATCTAGACATATTTTAATTTTAG 181 ATACATTCATTTTCGAGACAAGTAATTCCGAATGGAGGGAGTACCCATGCATATTCGTCT 241 CACGAGGGCAGCGCTGCAAATGCAAAGTCTCGCCGAGACAAGACCGGTCACCCTTTTCAT 301 GAGCTTGATCTCTTGGTAAGCAGCCCCCGCCGGACCATCATAATAACTTCATAAGCCGGG 361 AAAGACCCATTTGTGGTACGTACTAATACTATATTTGTGCGGTTGTGCGCATGAGATAAG 421 ATCCGGTTGAGGGTGGCGCGCATAAAAAATGGGCTATGTCAAAGCAATATCCCCTGAGCC 481 TCCATCCATGAACCAGTAGCGTCCGTCAACTACACGAACGAGCGACGAGGCCGCGCGCTA 541 CGAGCGCCACCATATACGTACGTATATATTAGTGGATCGGGCCATTAGCATAAGATCTCC 601 ATGCATGCATGTCGGATAGTACATCTCGAAATAGTCTTTCGCCCCGCTTTATCTCGGATG 661 CACCTAGTAGCCACATAGACAGGCCAAATCATCGCTTGCTAAAAGAACTGAGCTAGTAGT 721 AGTACTGGCATCTCTTGATGTGCCTCGTTGAAATTCAAACCGACCATTAACTTTCCCCGA 781 TCAGAGGAACCGGTCCGGATCCGATCGTTAGTTCGGCGACGGGCGACTTGATCCCGTCTG 841 TTTAAGCACTAGTAGTAGCAGATCACTCATCACATGGACGGACCGCTGCTAATAATTAAT 901 AGTATACCTGCCTGCTGTGCATATACAAGTCCTGGTAAAAGTAGCAGCCACACAAATGCA 961 GTCAACGCTTCGTTTGACTTGACTCGCTCAGGCCCGTAGCCGTACTCCACTGGATCTGGA 1021 TGGAACGCCCGCTTCGCCGGAGCTGCCTGGTCAGACTTCTCCACGCACGCACGACCGACC 1081 ATGGGCAGTCAAACTTCGGATGCCACGTCGACGTCCACGTTGTCGGTCGCATGCGGACGT 1141 GCGTGTGCAGGTCGTCGGAACTTGCGTGGTACAGTACGAGACTACTCCGTACAAGCGAGT 1201 AGAAGTGCACCACGTATACGTGCCGGGCCCGTTTACCTGCAGTAACGGAACCGTGCACGC 1261 TTTGGCTATACGTGCGCATGCAGCAGGCTGCACGTCGATGCCGTGCAGGTTTTATAATGT 1321 AGGAGTATACTGTAACTACCTTACAATTAATAACCATGGATGGATGCTTCGAAATGAAGC 1381 ATGGAGGAAGCCCGACGTCACACAGTTCGATCGCCCGATCCCTCGTTTTTCCCGGCCGGG 1441 GAAGAGACAAGAGAAACAGAGCTTTGCCCTTTTCGATCGTCTGGTCTGTCCCAACAGACT 1501 CTCCGTCCTCATTAATCAAGTCCAAAACAGGAATACATGCAGCAATACTGTATGCTTGCC 1561 AAATTAGCAATCACTATCACGTCAACCGGGGGCGATTAACAATGGCCCCTCCGTATGAAA 1621 AACTAACTCGATGGGAGCACCAGGCTAGCCATCGTACACGCACGTCCCGGCCGGTGAATG 1681 TTTCGACCGTCTGGGTACGAGTCTGACCCGCTCGAAGGTGCCACGCCCCTGCCTGCCGGG 1741 CGCCGGCGACCTGATCCACCACCACCCGACGCGCGGCTCGCCAGCGGGAACAGTCAGTCG 1801 CGCGCGTGGACGGCGAGTCTCGCCTCTACCAACGTGTGGCTACGTGTAACCGTGCTCCGT 1861 AAAACCGTGTTCGTTTTACCTTACCTTTCTCGCGCGCACACACGTCGCCGCCAATACATG 1921 TTTCGCGTCATTTTCTCCACGCAATAACTTTGGCGCGAACGGGTCTCCGATCGAGCGGCA 1981 TCAAATCAATCAACCCAACAAAAGTGATCCGACGTCACACAATTCGATCCCCCAAGAAAC 2041 GGGGCAGCACATTTGCCGTTTTCTTGCCGGTCCCAACGAACTCTCCGTCCTAATTTAACG 2101 TCAGTTTTTTTTCTCCGCCCGCGTTGATGATCCCGATAACGAGCAAGCTAGCCAGACGCG 2161 TCGGTTTTTGTCCTGCCTAGCTAGGAGTATCTCCAAGTAACCTACCTACGCGGGACAAAA 2221 CTATGGCCAGATATAGATATACTAGTCAAACGATGGCAACAAGAAAAAAAACTAGTCAAG 2281 AATAATACTCCCTCCATTCTAAATTACTTGTCGCAGGTATGAATGTATCTAGATGTATTT 2341 TAGTTCTAGATACATCCATTTCTGCAACGAGTAATTTGAAACGGAGGGAGTACTACGGAT 2401 TCCCTAAAGAAAAAAATACTACTAAAAACTAGTACTAGTAGTAAAGTGACCGTCCCCATC 2461 AAGAAATACTACGGGACCGACCGGGTGTCCCCCCTCGCCCCGGCCCGGTGCCGGCCGAGC 2521 ACCCAGAGCGCCATCGCTGGATCAACCACCCCGTCCAACCTCGCGCTAGGAAACATAGGT 2581 CGTTTCAGCCGAAACCCGCCACTCGACATTCGTATCAGCTCTAGGCAGGTCTCCCGCTCC 2641 GCAGCGCCGCTGCCGAGCCACCCGGCCGGCGCGCAGGCCTAGGTTTGACCCGGCCGCCGG 2701 GCGCCCGGCCGATAAAAGGCCCCGCGCGGCAGCTCCCTCCCACCCGGTTGCCACGCACAC 2761 ACTTCGCCACAGCAGAAACAAGCTAGACACACAACGTACCTGCGTACGTACGCTTTCCTT 2821 CTCCTTGCTTGCTCCGGCCGGCCGGCCACGTAGAATAGATACCTGGCCAGGTAGGTACCT 2881 CGTTGGCTCAGACGATCGGTGGTTGGGCTCGGGCGCGCGCCTGTCCGGCTGAGGTGGCCG 2941 CCGTTCGCTCCGGCCAAGGAAAGAGGTTGTGCTCAGGACGGGCGGCGGGGAGCCATG